

(19)



(11)

EP 2 499 494 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention of the grant of the patent:
08.03.2017 Bulletin 2017/10

(51) Int Cl.:
G01N 33/577 ^(2006.01) **G01N 33/53** ^(2006.01)
G01N 33/50 ^(2006.01) **G01N 33/68** ^(2006.01)

(21) Application number: **10829274.9**

(86) International application number:
PCT/US2010/055997

(22) Date of filing: **09.11.2010**

(87) International publication number:
WO 2011/057250 (12.05.2011 Gazette 2011/19)

(54) **REAGENTS AND METHODS FOR DETECTING PNH TYPE II WHITE BLOOD CELLS AND THEIR IDENTIFICATION AS RISK FACTORS FOR THROMBOTIC DISORDERS**

REAGENZIEN UND VERFAHREN FÜR DEN NACHWEIS VON PNH-TYP-II-LEUKOZYTEN UND IHRE IDENTIFIZIERUNG ALS RISIKOFAKTOREN FÜR THROMBOTISCHE ERKRANKUNGEN

RÉACTIFS ET PROCÉDÉS DESTINÉS À DÉTECTER DES GLOBULES BLANCS ASSOCIÉS À UNE HPN DE TYPE II ET LEUR IDENTIFICATION COMME FACTEURS DE RISQUE POUR DES TROUBLES THROMBOTIQUES

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
 Designated Extension States:
BA ME

(30) Priority: **09.11.2009 US 280897 P**

(43) Date of publication of application:
19.09.2012 Bulletin 2012/38

(73) Proprietor: **Alexion Pharmaceuticals, Inc.**
New Haven, CT 06510 (US)

(72) Inventors:
 • **MOVALIA, Mayur**
Brewer, ME 04412 (US)
 • **ILLINGWORTH, Andrea**
Holden, ME 04429 (US)
 • **FAAS MCKNIGHT, Susan**
Old Lyme, CT 06371 (US)
 • **ROTHER, Russell, P.**
Oklahoma City, OK 73151 (US)

(74) Representative: **D Young & Co LLP**
120 Holborn
London EC1N 2DY (GB)

(56) References cited:
US-A1- 2007 116 710 US-B1- 6 593 095

- **D. ROBERT SUTHERLAND ET AL:** "Diagnosing PNH with FLAER and multiparameter flow cytometry", **CYTOMETRY PART B: CLINICAL CYTOMETRY**, vol. 72B, no. 3, 1 May 2007 (2007-05-01), pages 167-177, XP055064574, ISSN: 1552-4949, DOI: 10.1002/cyto.b.20151
- **HALL CLAIRE ET AL:** "Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH)", **BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US**, vol. 102, no. 10, 15 November 2003 (2003-11-15), pages 3587-3591, XP002482083, ISSN: 0006-4971, DOI: 10.1182/BLOOD-2003-01-0009
- **RICHARDS, S. J. ET AL.:** 'Application of Flow Cytometry to the Diagnosis of Paroxysmal Nocturnal Hemoglobinuria' **CYTOMETRY** vol. 42, 2000, pages 223 - 233, XP008153703
- **DWORACKI, G. ET AL.:** 'Flow cytometric analysis of CD55 and CD59 expression on blood cells in paroxysmal nocturnal haemoglobinuria' **FOLIA HISTOCHEMICA ET CYTOBIOLOGICA** vol. 43, no. 2, 2005, pages 117 - 120, XP008153705
- **BRODKSY, R. A. ET AL.:** 'Improved Detection and Characterization of Paroxysmal Nocturnal Hemoglobinuria Using Fluorescent Aerolysin' **AMERICAN JOURNAL OF CLINICAL PATHOLOGY** vol. 114, 2000, pages 459 - 466, XP008153663

EP 2 499 494 B1

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- 'Blood (ASH Annual Meeting Abstracts)', 2009 article MOVALIA, M. K. ET AL.: 'Identification and Clinical Significance of Type II Granulocytes Among Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Identified Using Multiparameter High-Sensitivity Flow Cytometry.', page 114, XP008153390
- HALL, C. ET AL.: 'Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH)' BLOOD vol. 102, 2003, pages 3587 - 3591, XP002482083
- 'Blood (ASH Annual Meeting Abstracts)', 2006 article HILL, A. ET AL.: 'The Incidence and Prevalence of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Survival of Patients in Yorkshire', page 108, XP008153661
- MOYO, V. M. ET AL.: 'Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays' BRITISH JOURNAL OF HAEMATOLOGY vol. 126, 2004, pages 133 - 138, XP008153402

DescriptionCross-Reference to Related Applications

5 **[0001]** This application claims priority to and the benefit of U.S. Provisional Patent Application Serial No. 61/280,897, filed November 9, 2009, and entitled "Reagents and methods for detecting PNH type II cells".

Sequence Listing

10 **[0002]** The instant application contains a Sequence Listing which has been submitted via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on November 5, 2010, is named ALXN150WO1.txt, and is 26,000 bytes in size.

Technical Field

15 **[0003]** The field of the invention is medicine, immunology, molecular biology, and protein chemistry.

Background

20 **[0004]** Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, debilitating disease that is characterized by, among other things, abnormal hematopoiesis, complement-mediated intravascular hemolysis, and a propensity for thrombosis. See, e.g., Rosse and Nishimura (2003) *IntJHematol* 77(2): 121-124 and Brodsky (2008) *Blood Rev* 22(2):65-74. PNH is caused by a somatic mutation in the X-linked phosphatidylinositol glycan complementation class A (PIGA) gene, which encodes an enzyme that is necessary for the initial step of glycosylphosphatidylinositol (GPI) anchor biosynthesis. See
25 Miyata et al. (1993) *Science* 259:1318-1320 and Bessler et al. (1994) *EMBO J* 13:110-117. GPI anchors attach a number of proteins to the surface of hematopoietic cells. These so called GPI-anchored proteins include, among others, complement regulatory proteins such as CD55 (DAF) and CD59. Depending on the type of mutation that befalls the PIGA gene, a partial or complete loss of GPI anchor biosynthesis can result, which corresponds to a partial or complete loss in the presence of GPI-anchored proteins (e.g., GPI-anchored CD55 and CD59) on the cell surface. See Rosse (1997)
30 *Medicine* 76:63-93. The partial or complete absence of complement regulatory proteins on the surface of red blood cells (RBCs) results in the heightened sensitivity of these cells for complement-mediated lysis and associated symptoms of PNH in afflicted patients. See Nicholson-Weller et al. (1983) *Proc Natl Acad Sci USA* 80:5066-5070 and Yamashina et al. (1990) *N Engl J Med* 323:1184-1189.

[0005] Traditionally, diagnosis of PNH and monitoring of PNH patients involved analysis of CD55 and CD59 expression on the surface of RBCs and granulocytes using flow cytometry. Sutherland et al. (2009) *Am J Clin Pathol* 132:564-572.
35 More recently developed diagnostic methods for PNH have employed a recombinant, non-lytic form of the bacterial protein aerolysin, which binds to GPI-anchors on the surface of hematopoietic cells. See U.S. Patent No. 6,593,095 issued to Buckley and Brodsky. Both traditional and new methods have allowed medical practitioners to classify RBCs or white blood cells from PNH patients into one of three groups: *Type I* cells having normal or nearly normal cell-surface expression of GPI-anchored proteins; PNH *Type III* cells, which have nil or completely absent cell-surface expression of GPI-anchored proteins; and PNH *Type II* cells having an intermediate level of cell-surface expression of GPI-anchored proteins. Brodsky et al. (2000) *Am J Clin Pathol* 114:459-466. The characterization of Type II cells among white blood cell lineages has not been performed due to the difficulty in distinguishing these cells from normal Type I white blood cells.
40

Summary

45 **[0006]** The disclosure is based, at least in part, on the discovery by the inventors that patients having a PNH Type II white blood cell population of at least 1.2% or a PNH Type II red blood cell population of at least 0.02% are more likely to have thrombocytopenia as compared to patients who do not have PNH Type II cell populations or who have PNH Type II cell populations that are smaller than 1.2% or 0.02% for white and red blood cells, respectively. Patients with thrombocytopenia resulting from platelet destruction are much more likely to develop thrombosis, and among PNH patients, thrombosis is the leading cause of death. Accordingly, the present invention provides a method for predicting whether a patient afflicted with paroxysmal nocturnal hemoglobinuria (PNH) is at an increased risk for developing thrombosis, the method comprising:
50

55 determining the percentage of PNH Type II granulocytes of the total granulocytes in a whole blood sample from a patient; and
predicting whether the patient is at an increased risk for developing thrombosis, wherein the patient is at an increased

risk for developing thrombosis if the percentage of PNH Type II granulocytes is greater than or equal to 1.2%.

[0007] There are described methods for determining whether a patient is at an increased risk for thrombocytopenia and/or thrombosis based on the relative population of PNH

Type II cells in the patient. Identification of the nexus between PNH Type II cells and thrombocytopenia was aided, in part, by the development of improved methods for detecting PNH Type II cells.

[0008] There are described reagents and methods useful for detecting PNH Type II cells (e.g., Type II white blood cells and/or Type II red blood cells) in, e.g., biological samples from patients. The disclosure also describes methods for diagnosing and treating patients based on the presence or amount of PNH Type II cells in the patient. For example, the disclosure features a method for determining risk of thrombocytopenia in a patient based on the percentage of PNH Type II white blood cells detected in a biological sample from a patient suspected of having PNH. The diagnostic methods described herein have a number of advantages over prior art methods. For example, the methods described herein can more effectively separate PNH Type II white blood cells from Type I cells, which allows for a more accurate and precise measurement of the percentage of the Type II cells in a biological sample, as well as a more accurate assessment of the total PNH clone size, which comprises both Type II and Type III cells. In addition, PNH diagnostic methods that rely on GPI-expression on Type II RBCs can be unreliable because of a high turnover of red blood cells (the inherent shorter life-span of PNH Type III RBCs due to elevated sensitivity to complement-mediated lysis) and frequent RBC transfusions received by PNH patients. Therefore, the diagnostic methods described herein not only allow a practitioner to accurately and precisely quantify the percentage of Type II white blood cells in a biological sample, and thus the total abnormal clone size in the sample, but the methods are also more reliable than prior methods that relied on detecting relatively unstable populations of PNH Type II RBCs.

[0009] The disclosure features a method for predicting whether a patient is at an increased risk for thrombosis. The method includes determining whether a patient is at an increased risk for thrombosis based on the percentage of PNH Type II cells of the total number of cells of the same histological type (same lineage) in a biological sample from the patient indicates that the patient is at an increased risk for thrombosis.

[0010] The disclosure features a method for predicting whether a patient is likely to be thrombocytopenic. The method includes determining whether a patient is likely to be thrombocytopenic based on the percentage of PNH Type II cells (e.g., Type II red blood cells and/or Type II white blood cells) of the total number of cells of the same histological type (same lineage) in a biological sample from the patient indicates that the patient is likely to be thrombocytopenic.

[0011] The disclosure features a method for determining whether a patient is at an increased risk for thrombosis. The method includes providing (or receiving) information on the percentage of PNH Type II cells of the total cells of the same histological type (same lineage) in a biological sample from a patient; and determining whether a patient is at an increased risk for thrombosis, wherein the percentage of PNH Type II cells of the total number of cells of the same histological type in the biological sample indicates that the patient is at an increased risk for thrombosis.

[0012] The disclosure features a method for predicting whether a patient is at risk for developing thrombosis, which method includes determining the percentage of PNH Type II cells in a biological sample from a patient; and providing a prediction of whether the patient is at an increased risk for thrombosis, wherein the percentage of PNH Type II cells of the total number of cells of the same histological type in the biological sample indicates that the patient is at an increased risk for thrombosis.

[0013] The PNH Type II cells may be white blood cells (e.g., granulocytes or monocytes). Alternatively, the PNH, Type II cells may be red blood cells.

[0014] In any of the methods described herein, the combination of a percentage of PNH type II white blood cells that is greater than or equal to 1.2% and a percentage of PNH type II red blood cells that is greater than or equal to 0.02% is predictive of whether the patient is at an increased risk of developing thrombosis or is likely to be thrombocytopenic.

[0015] In any of the methods described herein, the patient may be at an increased risk of developing thrombosis (and/or likely to be thrombocytopenic) when the percentage of PNH Type II white blood cells is at least 1.2 (e.g., at least 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 65.3, or 70 or more) %. In any of the methods described herein, the patient may be at an increased risk of developing thrombosis (and/or likely to be thrombocytopenic) when the percentage of PNH Type II red blood cells is at least 0.02 (e.g., at least 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 71, 71.3, or 75 or more) %.

[0016] In any of the methods described herein, a PNH Type II white blood cell population that is between 1.2% to 65%, inclusive of 1.2% and 65%, may indicate that the patient is at an increased risk for thrombosis (and/or likely to be thrombocytopenic). A PNH Type II white blood cell population that is greater than or equal to 5% may indicate that the patient is at an increased risk for thrombosis (and/or likely to be thrombocytopenic). A PNH Type II white blood cell population that is greater than or equal to 10%, 20%, or even 50% may indicate that the patient is at an increased risk

for thrombosis (and/or likely to be thrombocytopenic).

[0017] Any of the methods described herein can further include obtaining the biological sample from the patient. The biological sample can be, e.g., a whole blood sample.

[0018] The disclosure features a method for predicting whether a patient is at an increased risk for developing thrombosis (and/or likely to be thrombocytopenic). The method includes determining the percentage of Type II white blood cells of the total white blood cells of the same histological type in a biological sample from a patient; and predicting whether the patient is at an increased risk for developing thrombosis, wherein the patient is at an increased risk for developing thrombosis (and/or likely to be thrombocytopenic) if the percentage of Type II white blood cells is greater than or equal to 1.2 (e.g., greater than or equal to 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 65.3, or 70 or more) %.

[0019] The disclosure features a method for predicting whether a patient is at an increased risk for developing thrombosis (and/or likely to be thrombocytopenic). The method includes determining the percentage of Type II red blood cells of the total red blood cells of the same histological type in a biological sample from a patient; and predicting whether the patient is at an increased risk for developing thrombosis (and/or likely to be thrombocytopenic), wherein the patient is at an increased risk for developing thrombosis (and/or likely to be thrombocytopenic) if the percentage of Type II red blood cells is greater than or equal to 0.02 (e.g., greater than or equal to 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 5, 6, 7, 8, 9, 10, 11, 12, 3, 4, 15, 16, 7, 8, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 71, 71.3, or 75 or more) %.

[0020] The disclosure features a method for selecting a therapy for a patient, which method includes selecting one or both of an anti-thrombotic therapy and an anti-thrombocytopenic therapy for a patient determined to have a PNH Type II white blood cell population of greater than or equal to 1.2 (e.g., greater than or equal to 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 65.3, or 70 or more) % and/or a PNH Type II red blood cell population of greater than or equal to 0.02 (e.g., greater than or equal to 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 71, 71.3, or 75 or more) %.

[0021] According to one aspect of the invention there is provided a method for selecting a therapy for a patient afflicted with paroxysmal nocturnal hemoglobinuria (PNH), the method comprising: (a) determining the percentage of PNH type II granulocytes of the total granulocytes in a whole blood sample of the patient according to the method of the invention and (b) selecting one or both of an anti-thrombotic therapy and an anti-thrombocytopenic therapy for a patient determined to have a percentage of PNH Type II granulocytes of greater than or equal to 1.2%.

[0022] The disclosure features a method for treating a patient. The method includes administering to a patient in need thereof one or both of an anti-thrombotic therapy and an anti-thrombocytopenic therapy if the patient is determined to have a PNH Type II white blood cell population of greater than or equal to 1.2 (e.g., greater than or equal to 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 65.3, or 70 or more) % and/or a PNH Type II red blood cell population of greater than or equal to 0.02 (e.g., greater than or equal to 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2, 3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 71, 71.3, or 75 or more) %.

[0023] In any of the methods described herein, the anti-thrombocytopenic therapy can be, e.g., platelet transfusion.

[0024] The disclosure features a computer-based method for determining whether a patient is at an increased risk for developing thrombosis, which method includes receiving data including a medical profile of a PNH patient, the profile comprising information on the percentage of PNH Type II white blood cells of the total white blood cells of the same histological type (same lineage) in a biological sample from the patient; and processing at least the portion of the data containing the information to determine whether the patient is at an increased risk for developing thrombosis, wherein the patient is at an increased risk for developing thrombosis if the percentage of Type II white blood cells is greater than or equal to 1.2 (e.g., greater than or equal to 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 65.3, or 70 or more) %.

[0025] The disclosure features a computer-based method for determining whether a patient is at an increased risk for developing thrombosis, which method includes receiving data including a medical profile of a PNH patient, the profile comprising information on the percentage of PNH Type II red blood cells of the total red blood cells of the same histological type (same lineage) in a biological sample from the patient; and processing at least the portion of the data containing the information to determine whether the patient is at an increased risk for developing thrombosis, wherein the patient

is at an increased risk for developing thrombosis if the percentage of Type II red blood cells is greater than or equal to 0.02 (e.g., greater than or equal to 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 71, 71.3, or 75 or more) %.

[0026] The disclosure features a computer-based method for determining whether a patient is at an increased risk for developing thrombosis, which method includes providing information on the percentage of PNH Type II white blood cells of the total white blood cells of the same histological type (same lineage) in a biological sample from the patient; inputting the information into a computer; and calculating a parameter indicating whether the patient is at an increased risk for thrombosis using the computer and the input information, wherein the patient is at an increased risk for developing thrombosis if the percentage of Type II white blood cells is greater than or equal to 1.2 (e.g., greater than or equal to 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 65.3, or 70 or more) %.

[0027] The disclosure features a computer-based method for determining whether a patient is at an increased risk for developing thrombosis, which method includes providing information on the percentage of PNH Type II white blood cells of the total white blood cells of the same histological type in a biological sample from the patient; inputting the information into a computer; and calculating a parameter indicating whether the patient is at an increased risk for thrombosis using the computer and the input information, wherein the patient is at an increased risk for developing thrombosis if the percentage of Type II white blood cells is greater than or equal to 0.02 (e.g., greater than or equal to 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 71, 71.3, or 75 or more) %.

[0028] Any of the computer-based methods described herein can further include storing the parameter on a computer-readable medium and/or outputting the parameter.

[0029] In some embodiments, any of the methods described herein can include the step of monitoring the patient for the development of at least one symptom of thrombosis if the patient is at an increased risk of developing thrombosis. In some embodiments, any of the methods described herein can include selecting an anti-thrombotic therapy for the patient if the patient is at an increased risk of developing thrombosis. Any of the methods described herein can include administering to the patient an anti-thrombotic therapy if the patient is at an increased risk for developing thrombosis. The anti-thrombotic therapy can be, e.g., an anticoagulant or a thrombolytic agent. The anticoagulant can be, e.g., coumadin, heparin, or derivatives thereof. The thrombolytic agent can be, e.g., a tissue plasminogen activator, streptokinase, or a urokinase-type plasminogen activator.

[0030] In any of the methods described herein, a non-lytic variant form of aerolysin protein can be used to determine the percentage of PNH Type II white blood cells in the biological sample.

[0031] Any of the methods described herein can include recording the determined percentage of PNH Type II cells in the biological sample.

[0032] Any of the methods described herein can include recording the prediction of whether the patient is at an increased risk for developing thrombosis or whether the patient is not at an increased risk for developing thrombosis. The recordation can be on a computer-readable medium. The recordation can also be, e.g., on a tangible medium (e.g., a patient's physical record or chart).

[0033] The disclosure features a method for classifying white blood cells. The method contacting a plurality of white blood cells with a reagent that binds to: (i) GPI or (ii) a GPI-anchored protein; and classifying one or more of the white blood cells as PNH Type II cells based on the amount of reagent bound to the cells.

[0034] The disclosure features a method for classifying white blood cells, which method includes contacting a plurality of white blood cells with a reagent that binds to: (i) GPI or (ii) a GPI-anchored protein; interrogating at least a portion of the white blood cells contacted with the reagent based on the amount of reagent bound to the cells; and classifying one or more of the interrogated cells as PNH Type II cells.

[0035] The disclosure features a method for distinguishing between different white blood cell populations. The method includes contacting a plurality of white blood cells with a reagent that binds to: (i) GPI or (ii) a GPI-anchored protein; and distinguishing at least a portion of the white blood cells from other white blood cells of the plurality based on the amount of reagent bound the cells, wherein the PNH Type II white blood cells, if present, are sufficiently distinguished from the Type I white blood cells and PNH Type III cells of the same histological type (same lineage) to allow the percentage of PNH Type II white blood cells of the total white blood cells of the same histological type in the plurality to be determined. The method can also include determining the percentage of PNH Type II white blood cells.

[0036] The disclosure features a method for determining the percentage of PNH Type II white blood cells in a sample, which method includes interrogating a plurality of white blood cells contacted with a reagent based on the amount of reagent bound to the cells, wherein the reagent binds to: (i) GPI or (ii) a GPI-anchored protein, wherein the interrogating sufficiently distinguishes the PNH Type II white blood cells, if present, from the Type I white blood cells and PNH Type

III cells of the same histological type to allow the percentage of PNH Type II white blood cells of the total white blood cells of the same histological type in the plurality to be determined; and determining the percentage of PNH Type II white blood cells.

[0037] In any of the methods described herein, the plurality of white blood cells may be contacted with a reagent that binds to GPI and a reagent that binds to a GPI-linked protein.

[0038] In any of the methods described herein, the distinguishing or interrogating of white blood cells (and/or the determination of the percentage of PNH Type II white blood cells) includes flow cytometry.

[0039] In any of the methods described herein, the plurality of white blood cells to be interrogated may be obtained from a patient having, suspected of having, or at risk of developing PNH. The patient may be one for whom a percentage of PNH Type II red blood cells has been previously determined, but was suspect and/or inconclusive.

[0040] Any of the methods described herein can further include recording the percentage of PNH Type II white blood cells. The recordation can be on a computer-readable medium or a tangible medium (e.g., a patient chart or record).

[0041] In some embodiments of any of the methods described herein, the reagent can bind to a human GPI moiety. The reagent can be, e.g., an antibody or an antigen-binding fragment thereof, or an aerolysin protein. The aerolysin protein can be, e.g., a variant form of aerolysin protein that is non-lytic or is substantially non-lytic as compared to the wildtype form of the protein. The non-lytic or substantially non-lytic aerolysin protein can comprise the amino acid sequence depicted in SEQ ID NO:2 or 7 wherein the threonine at position 253 is substituted with a cysteine and the alanine at position 300 is substituted for a cysteine.

[0042] In some embodiments of any of the methods described herein, the reagent can bind to a GPI-anchored protein. For example, the reagent can be, e.g., an antibody or an antigen-binding fragment thereof that binds to a GPI-anchored protein. The GPI-anchored protein can be, e.g., alkaline phosphatase, 5' nucleotidase acetylcholinesterase, dipeptidase, LFA-3, NCAM, PH-20, CD55, CD59, Thy-1, Qa-2, CD 14, CD33, CD16 (the Fc_γ receptor III), carcinoembryonic antigen (CEA), CD24, CD66b, CD87, CD48, CD52, or any other GPI-anchored protein that is known in the art and/or set forth herein.

[0043] A patient determined to have a PNH Type II white blood cell population of greater than or equal to 1.2% or a PNH Type II red blood cell population of greater than or equal to 0.02% can be diagnosed as having PNH.

[0044] A patient diagnosed as having PNH or a previously diagnosed PNH patient who is determined to have a PNH Type II white blood cell population greater than or equal to 1.2% or a PNH Type II red blood cell population that is greater than or equal to 0.02% can be prescribed and/or treated with a complement inhibitor such as, but not limited to, eculizumab.

[0045] The disclosure features an antibody or an antigen-binding fragment thereof that binds to a human GPI moiety. The antibody or antigen-binding fragment thereof can be, e.g., a recombinant antibody, a diabody, a chimerized or chimeric antibody, a deimmunized human antibody, a fully human antibody, a single chain antibody, an Fv fragment, an Fd fragment, an Fab fragment, an Fab' fragment, and an F(ab')₂ fragment.

[0046] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. In case of conflict, the present document, including definitions, will control. Preferred methods and materials are described below, although methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the presently disclosed methods and compositions.

[0047] Other features and advantages of the present disclosure, e.g., methods for determining risk of thrombocytopenia or thrombosis in a subject, will be apparent from the following description, the examples, and from the claims.

Brief Description of the Drawings

[0048]

Fig. 1 is a two color dot plot depicting a population of human peripheral blood granulocytes that were incubated with a solution containing both a non-lytic variant of aerolysin conjugated with Alexa Fluor® 488 and an antibody that binds to CD24 conjugated to phycoerythrin (PE). The non-lytic aerolysin binds specifically to the GPI anchor, and therefore cells expressing any GPI-anchored proteins are labeled with this fluorescent protein. CD24 is a GPI-linked protein expressed on granulocytes, so cells expressing CD24 will be bound by both the anti-CD24 antibody and the non-lytic aerolysin. The X-axis represents the log intensity of detectable signal produced from the aerolysin conjugate bound to the cells and the Y-axis represents the log intensity of the detectable signal produced from the anti-CD24 antibody conjugate bound to the cells. Three populations of granulocytes are revealed by this analysis: Type III cells, which are devoid of GPI-linked proteins and thus appear unlabeled with either the anti-CD24 antibody and the non-lytic aerolysin; Type I granulocytes, which express high levels of GPI-linked proteins relative to cells lacking GPI-anchors; and Type II granulocytes, which express intermediate levels of GPI-linked proteins and thus are labeled with both the anti-CD24 and non-lytic aerolysin at lower levels than those seen on normal (Type I) granulocytes.

Fig. 2 is a scatter plot depicting the absolute platelet count versus the percentage of PNH Type II granulocytes in the blood of patients with PNH. The Y-axis represents the platelet count in 1 μL of patient blood ($\times 10^{-3}$) and the X-axis represents the percentage of PNH Type II granulocytes within the total granulocyte population. The left half of the plot is a distribution of the platelet counts observed among PNH patients (N= 141) that have no detectable PNH Type II granulocyte populations. The right half of the plot is a distribution of the platelet counts observed among PNH patients (N=19) who have detectable PNH Type II granulocyte populations.

Detailed Description

[0049] The present disclosure features a variety of diagnostic and therapeutic applications that are useful for, *inter alia*, determining whether a patient has a PNH Type II cell population and/or is at an increased risk for developing thrombocytopenia and/or thrombosis. The disclosure also features reagents that can be used in the methods. While in no way intended to be limiting, exemplary reagents, conjugates, and methods for using any of the foregoing are elaborated on below and are exemplified in the working Examples.

Reagents

[0050] The disclosure features a number of reagents that are useful in the diagnostic and therapeutic methods described herein. In some embodiments, the reagent binds to a glycosylphosphatidylinositol (GPI) moiety, which anchors many cell surface proteins to the cell membrane. GPI moieties generally contain a core of ethanolamine- HPO_4 -6Man α -1-2Man α -1-6Man α -1-4GlcNH $_2$ -1-6myo-inositol-1 HPO_4 -diacyl-glycerol (or alkylacylglycerol or ceramide). See, e.g., Paulick and Bertozzi (2008) *Biochemistry* 47(27):6991-7000. However, a number of variations on this core structure have been reported. For example, the glycan core can be modified with side chains such as, but not limited to, phosphoethanolamine, mannose, galactose, sialic acid, or other sugars. *Id.*

[0051] In some embodiments, the reagent can be an aerolysin protein, e.g., a non-lytic aerolysin protein. Aerolysin is a channel-forming cytolytic protein that is expressed by virulent *Aeromonas* species such as, but not limited to, *Aeromonas hydrophila* and *Aeromonas salmonicida*. Aerolysin is secreted from the bacterial cell as a 52 kDa precursor that is converted to the active form (activated) by proteolytic removal of a C-terminal peptide. The aerolysin precursor can be activated by host proteases as

well as proteases secreted by an aerolysin-expressing bacterium. Once bound to a cell, aerolysin oligomerizes to produce channels in, and ultimately lyse, the cell (Howard and Buckley (1985) *J Bacteriol* 163:336-340).

[0052] The amino acid sequences of the aerolysin polypeptide produced by each of various members of the *Aeromonas* family are highly conserved. Accordingly, an aerolysin polypeptide, as used herein, can be from any species of *Aeromonas* such as, but not limited to, *A. hydrophila*, *A. caviae*, *A. veronii* (biotype *sobria*), *A. veronii* (biotype *veronii*), *A. jandaei*, *A. salmonicida*, and *A. schubertii*.

[0053] The aerolysin polypeptide may be from *A. hydrophila* or *A. salmonicida*. The aerolysin polypeptide may be a proform containing a 24 amino acid signal peptide. The proform aerolysin polypeptide can have, or consist of, a polypeptide having the amino acid sequence depicted in SEQ ID NO:1 or SEQ ID NO:6.

[0054] In some embodiments, the aerolysin polypeptide is a form of the protein in which the signal sequence has been removed. For example, the aerolysin polypeptide can have, or consist of, a polypeptide having an amino acid sequence depicted in SEQ ID NO:2 or SEQ ID NO:7.

[0055] The aerolysin polypeptide may be an active form of the protein. For example, the aerolysin polypeptide can have, or consist of, a polypeptide having an amino acid sequence depicted in SEQ ID NO:3.

[0056] As used herein, "polypeptide," "peptide," and "protein" are used interchangeably and mean any peptide-linked chain of amino acids, regardless of length or post-translational modification. The aerolysin polypeptides described herein can contain or be wildtype proteins or can be variants of the wild-type polypeptides that have not more than 50 (e.g., not more than one, two, three, four, five, six, seven, eight, nine, ten, 12, 15, 20, 25, 30, 35, 40, or 50) conservative amino acid substitutions. Conservative substitutions typically include substitutions within the following groups: glycine and alanine; valine, isoleucine, and leucine; aspartic acid and glutamic acid; asparagine, glutamine, serine and threonine; lysine, histidine and arginine; and phenylalanine and tyrosine.

[0057] The aerolysin polypeptides described herein also include "GPI-binding fragments" of the polypeptides, which are shorter than the full-length, proform polypeptides, but retain at least 10% (e.g., at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 50%, at least 55%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, at least 99%, at least 99.5%, or 100% or more) of the ability of the active polypeptide to bind to a GPI moiety. GPI-binding fragments of an aerolysin polypeptide include terminal as well internal deletion variants of the protein. Deletion variants can lack one, two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid segments (of two or more amino acids) or non-contiguous single

amino acids. GPI-binding fragments can be at least 40 (e.g., at least 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 250, 300, or 325 or more) amino acid residues in length (e.g., at least 40 contiguous amino acid residues of SEQ ID Nos:1-3).

[0058] The GPI-binding fragment of an aerolysin polypeptide may be less than 400 (e.g., less than 350, 325, 300, 275, 250, 225, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, 100, 95, 90, 85, 80, 75, 60, 50, 49, 48, 47, 46, 45, 44, 43, 42, 41, or 40) amino acid residues in length (e.g., less than 400 contiguous amino acid residues of SEQ ID NOs:1-3). The GPI-binding fragment of an aerolysin polypeptide may be at least 40, but less than 400, amino acid residues in length.

[0059] The GPI-binding fragment of an aerolysin polypeptide can include, or consist of, a polypeptide having the following amino acid sequence: L D P D S F K H G D V T Q S D R Q L V K T V V G W A V N D S D T P Q S G Y D V T L R Y D T A T N W S K T N T Y G L S E K V T T K N K F K W P L V G E T E L S I E I A A N Q S W A S Q N G G S T T T S L S Q S V R P T V P A R S K I P V K I E L Y K A D I S Y P Y (SEQ ID NO:4).

[0060] The GPI-binding fragment of an aerolysin polypeptide can include, or consist of, a polypeptide having the following amino acid sequence: L D P D S F K H G D V T Q S D R Q L V K T V V G W A V N D S D T P Q S G Y D V T L R Y D T A T N W S K T N T Y G L S E K V T T K N K F K W P L V G E C E L S I E I A A N Q S W A S Q N G G S T T T S L S Q S V R P T V P A R S K I P V K I E L Y K C D I S Y P Y (SEQ ID NO:5).

[0061] The aerolysin polypeptide can have an amino acid sequence that is, or is greater than, 70 (e.g., 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100) % identical to the aerolysin sequence having the amino acid sequence depicted in any one of SEQ ID NOs: 1-3, 6, or 7 (see below).

[0062] Percent (%) amino acid sequence identity is defined as the percentage of amino acids in a candidate sequence that are identical to the amino acids in a reference sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR) software. Appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full-length of the sequences being compared can be determined by known methods.

[0063] Depending on the intended application, in some embodiments it may be preferable to use a variant aerolysin polypeptide that lacks the ability to lyse cells. Such variant forms of the aerolysin polypeptide are known in the art and described in, e.g., Brodsky et al. (2000) *Am J Clin Pathol* 114:459-466. The non-lytic, variant form of aerolysin may contain, or consist of, the amino acid sequence depicted in SEQ ID NO:2 or SEQ ID NO:7 wherein one or more of: the histidine at position 132 is substituted for an asparagine (His132Asn); the glycine at position 202 is a cysteine; the threonine at position 253 is a cysteine and the alanine at position 300 is a cysteine; and the threonine at position 225 is a glycine. One exemplary non-lytic variant of aerolysin comprises the amino acid sequence depicted in SEQ ID NOs: 2 or 7, wherein the threonine at position 253 is a cysteine and the alanine at position 300 is a cysteine. As described above, the variant forms will retain the ability to bind to GPI moieties.

[0064] The variant aerolysin polypeptide may have less than 10 (e.g., less than 9, 8, 7, 6, 5, 4, 3, 2, or 1) % of the ability of the non-variant counterpart aerolysin polypeptide to lyse target cells. The variant aerolysin polypeptide may have no detectable cytolytic activity.

[0065] Methods for determining whether a variant aerolysin polypeptide binds to a GPI moiety are known in the art and exemplified in the working examples. For example, cell-based methods for detecting the binding between a variant aerolysin polypeptide and a GPI moiety on a cell surface can be determined using flow cytometry techniques and a detectably-labeled (e.g., a fluorophore-labeled) variant aerolysin polypeptide. See, e.g., Hong et al. (2002) *EMBO J* 21(19):5047-5056.

[0066] Likewise, methods for detecting and/or quantitating the cytolytic activity of an aerolysin polypeptide or variant thereof are also known in the art. For example, the hemolytic activity of a variant Aerolysin polypeptide can be determined by contacting the variant polypeptide to normal human erythrocytes and measuring the amount of hemoglobin released from the erythrocytes. See, e.g., Howard and Buckley (1982) *Biochemistry* 21(7):1662-1667; Avigad and Bernheimer (1976) *Infection and Immunity* 13(5):1378-1381; Garland and Buckley (1988) *Infection and Immunity* 56(5):1249-1253; and Bernheimer and Avigard (1974) *Infection and Immunity* 9:1016-1021. A decreased amount, or the absence of, cytolytic activity by the variant, as compared to the amount of cytolytic activity possessed by the non-variant counterpart polypeptide, is an indication that the variant polypeptide has reduced or absent cytolytic activity.

[0067] Methods for obtaining an aerolysin polypeptide, or producing a variant of the polypeptide as described herein, are known in the art of molecular biology and exemplified in the working Examples. See, e.g., Sambrook et al. (1989) "Molecular Cloning: A Laboratory Manual, 2nd Edition," Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. and Ausubel et al. (1992) "Current Protocols in Molecular Biology," Greene Publishing Associates. Template DNA encoding an aerolysin polypeptide can be obtained from any of the *Aeromonas* species described herein using standard techniques (see, e.g., Sambrook et al. (1989), *supra*). For example, Howard et al. describes the isolation and characterization of a nucleic acid sequence encoding an aerolysin polypeptide from *Aeromonas hydrophila* (Howard et al. (1987) *J Bacteriol* 169(6):2869-2871). An aerolysin polypeptide isolated from *Aeromonas salmonicida* is described in

Buckley (1990) *Biochem. Cell Biol.* 68:221-224 and Wong et al. (1989) *JBacteriol.* 171:2523-2527.

[0068] An aerolysin polypeptide can contain internal or terminal (carboxy or amino-terminal) irrelevant or heterologous amino acid sequences (e.g., sequences derived from other proteins or synthetic sequences not corresponding to any naturally occurring protein). The sequences can be, for example, an antigenic tag (e.g., FLAG, polyhistidine, hemagglutinin (HA), glutathione-S-transferase (GST), or maltose-binding protein (MBP)). Heterologous sequences can also include proteins useful as diagnostic or detectable markers, for example, luciferase, green fluorescent protein (GFP), or chloramphenicol acetyl transferase (CAT).

[0069] Exemplary aerolysin polypeptides as well as methods for preparing and purifying the polypeptides are described in U.S. provisional patent application serial no. 61/200,6555.

[0070] In some embodiments, the reagent can be an antibody that binds to a GPI moiety. Antibodies that bind to non-human GPI moieties have been identified and isolated. See, e.g., Naik et al. (2006) *Infection and Immunity* 74(2):1412 (isolation of a naturally-occurring antibody that binds to the GPI moieties of *Plasmodium falciparum*). As described in detail herein, it is well within the capability of an ordinarily skilled artisan to generate an antibody that binds to a human GPI moiety.

[0071] As used herein, the term "antibody" refers to a whole or intact antibody molecule (e.g., IgM, IgG (including IgG1, IgG2, IgG3, and IgG4), IgA, IgD, or IgE) or any antigen-binding fragment thereof. The term antibody includes, e.g., a chimerized or chimeric antibody, a humanized antibody, a deimmunized antibody, and a fully human antibody. Antigen-binding fragments of an antibody include, e.g., a single chain antibody, a single chain Fv fragment (scFv), an Fd fragment, an Fab fragment, an Fab' fragment, or an F(ab')₂ fragment. An scFv fragment is a single polypeptide chain that includes both the heavy and light chain variable regions of the antibody from which the scFv is derived. In addition, intrabodies, minibodies, triabodies, and diabodies (see, e.g., Todorovska et al. (2001) *J Immunol Methods* 248(1):47-66; Hudson and Kortt (1999) *J Immunol Methods* 231(1):177-189; Poljak (1994) *Structure* 2(12):1121-1123; Rondon and Marasco (1997) *Annual Review of Microbiology* 51:257-283)

are also included in the definition of antibody and are compatible for use in the methods described herein. Bispecific antibodies are also embraced by the term "antibody." Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. Methods for generating an antibody or a fragment thereof are discussed herein.

[0072] In some embodiments, the reagent can bind to a GPI-anchored protein. For example, the reagent can be an antibody that binds to a GPI-anchored protein. The

reagent can be a ligand for a GPI-anchored protein. GPI-anchored proteins are myriad and include, without limitation, alkaline phosphatase, 5' nucleotidase acetylcholinesterase, dipeptidase, LFA-3, NCAM, PH-20, CD55, CD59, Thy-1, Qa-2, CD14, CD33, CD16 (the Fc_γ receptor III), carcinoembryonic antigen (CEA), and CD52. Antibodies that bind to GPI-anchored proteins are well known in the art and are described in, e.g., Hall and Rosse (1996) *supra*, Richards et al. (2008) *Cytometry B Clin Cytom* 76B(1):47-55; Richards and Barnett (2007) *Clin Lab Med* 27(3):577-590; Luzzatto et al. (2006) *Int J Hematol* 84(2):104-112; and Thomason et al. (2004) *Am J Clin Pathol* 122(1):128-134. Such antibodies are also commercially available from, e.g., Santa Cruz Biotechnology, Inc. (Santa Cruz, California), Novus Biologicals (Littleton, Colorado), and R&D Systems (Minneapolis, MN).

[0073] Suitable methods for generating an antibody that binds to a GPI-anchored protein or a GPI moiety for use in the diagnostic and/or therapeutic methods described are well known in the art and described in the following section.

Methods for Generating an Antibody

[0074] Suitable methods for producing an antibody (e.g., an antibody that binds to a GPI moiety or a GPI-anchored protein), or antigen-binding fragments thereof, in accordance with the disclosure are known in the art and described herein. For example, monoclonal anti-CD55 antibodies may be generated using human CD55-expressing cells, a CD55 polypeptide, or an antigenic fragment of CD55 polypeptide, as an immunogen, thus raising an immune response in animals from which antibody-producing cells and in turn monoclonal antibodies may be isolated. The sequence of such antibodies may be determined and the antibodies or variants thereof produced by recombinant techniques. Recombinant techniques may be used to produce chimeric, CDR-grafted, humanized and fully human antibodies based on the sequence of the monoclonal antibodies as well as polypeptides capable of binding to a GPI-anchored protein or a GPI moiety.

[0075] Moreover, antibodies derived from recombinant libraries ("phage antibodies") may be selected using, e.g., cells expressing a GPI moiety or a GPI-anchored protein, recombinant GPI-linked proteins, or free GPI moieties as bait to isolate the antibodies or polypeptides on the basis of target specificity. The production and isolation of non-human and chimeric antibodies are well within the purview of the skilled artisan.

[0076] Recombinant DNA technology can be used to modify one or more characteristics of the antibodies produced in non-human cells. Thus, chimeric antibodies can be constructed in order to decrease the immunogenicity thereof in diagnostic or therapeutic applications. Moreover, immunogenicity can be minimized by humanizing the antibodies by CDR grafting and, optionally, framework modification. See, U.S. PatentNos. 5,225,539 and 7,393,648.

[0077] Antibodies can be obtained from animal serum or, in the case of monoclonal antibodies or fragments thereof, produced in cell culture. Recombinant DNA technology can be used to produce the antibodies according to established procedure, including procedures in bacterial or preferably mammalian cell culture. The selected cell culture system preferably secretes the antibody product.

5 [0078] A process for the production of an antibody disclosed herein includes culturing a host, e.g. *E. coli* or a mammalian cell, which has been transformed with a hybrid vector. The vector includes one or more expression cassettes containing a promoter operably linked to a first DNA sequence encoding a signal peptide linked in the proper reading frame to a second DNA sequence encoding the antibody protein. The antibody protein is then collected and isolated. Optionally, the expression cassette may include a promoter operably linked to polycistronic (e.g., bicistronic) DNA sequences encoding antibody proteins each individually operably linked to a signal peptide in the proper reading frame.

10 [0079] Multiplication of hybridoma cells or mammalian host cells *in vitro* is carried out in suitable culture media, which include the customary standard culture media (such as, for example Dulbecco's Modified Eagle Medium (DMEM) or RPMI 1640 medium), optionally replenished by a mammalian serum (e.g. fetal calf serum), or trace elements and growth sustaining supplements (e.g. feeder cells such as normal mouse peritoneal exudate cells, spleen cells, bone marrow macrophages, 2-aminoethanol, insulin, transferrin, low density lipoprotein, oleic acid, or the like). Multiplication of host cells which are bacterial cells or yeast cells is likewise carried out in suitable culture media known in the art. For example, for bacteria suitable culture media include medium LE, NZCYM, NZYM, NZM, Terrific Broth, SOB, SOC, 2 xYT, or M9 Minimal Medium. For yeast, suitable culture media include medium YPD, YEPD, Minimal Medium, or Complete Minimal Dropout Medium.

20 [0080] *In vitro* production provides relatively pure antibody preparations and allows scale-up production to give large amounts of the desired antibodies. Techniques for bacterial cell, yeast, plant, or mammalian cell cultivation are known in the art and include homogeneous suspension culture (e.g. in an airlift reactor or in a continuous stirrer reactor), and immobilized or entrapped cell culture (e.g. in hollow fibers, microcapsules, on agarose microbeads or ceramic cartridges).

25 [0081] Large quantities of the desired antibodies can also be obtained by multiplying mammalian cells *in vivo*. For this purpose, hybridoma cells producing the desired antibodies are injected into histocompatible mammals to cause growth of antibody-producing tumors. Optionally, the animals are primed with a hydrocarbon, especially mineral oils such as pristane (tetramethyl-pentadecane), prior to the injection. After one to three weeks, the antibodies are isolated from the body fluids of those mammals. For example, hybridoma cells obtained by fusion of suitable myeloma cells with antibody-producing spleen cells from Balb/c mice, or transfected cells derived from hybridoma cell line Sp2/0 that produce the desired antibodies are injected intraperitoneally into Balb/c mice optionally pre-treated with pristane. After one to two weeks, ascitic fluid is taken from the animals.

30 [0082] The foregoing, and other, techniques are discussed in, for example, Kohler and Milstein, (1975) Nature 256:495-497; U.S. Patent No. 4,376,110; Harlow and Lane, Antibodies: a Laboratory Manual, (1988) Cold Spring Harbor.

35 [0083] Techniques for the preparation of recombinant antibody molecules are described in the above references and also in, e.g.: WO97/08320; U.S. Patent No. 5,427,908; U.S. Patent No. 5,508,717; Smith (1985) Science 225:1315-1317; Parmley and Smith (1988) Gene 73:305-318; De La Cruz et al. (1988) Journal of Biological Chemistry 263:4318-4322; U.S. Patent No. 5,403,484; U.S. Patent No. 5,223,409; WO88/06630; WO92/15679; U.S. Patent No. 5,780,279; U.S. Patent No. 5,571,698; U.S. Patent No. 6,040,136; Davis et al. (1999) Cancer Metastasis Rev. 18(4):421-5; and Taylor et al. (1992) Nucleic Acids Research 20: 6287-6295; Tomizuka et al. (2000) Proc. Natl. Acad. Sci. USA 97(2): 722-727.

40 [0084] The cell culture supernatants are screened for the desired antibodies, preferentially by immunofluorescent staining of GPI or GPI-anchored protein-expressing cells, by immunoblotting, by an enzyme immunoassay, e.g. a sandwich assay or a dot-assay, or a radioimmunoassay.

45 [0085] For isolation of the antibodies, the immunoglobulins in the culture supernatants or in the ascitic fluid may be concentrated, e.g. by precipitation with ammonium sulfate, dialysis against hygroscopic material such as polyethylene glycol, filtration through selective membranes, or the like. If necessary and/or desired, the antibodies are purified by the customary chromatography methods, for example gel filtration, ion-exchange chromatography, chromatography over DEAE-cellulose and/or (immuno-) affinity chromatography, e.g. affinity chromatography with a GPI-moiety, a cell expressing GPI-anchors at its surface, a GPI-anchored polypeptide, a cell expressing a GPI-anchored protein at its surface, or with Protein-A or -G.

50 [0086] There is described a process for the preparation of a bacterial cell line secreting antibodies directed against a GPI moiety or a GPI-anchored protein in a suitable mammal. For example, a rabbit is immunized with a GPI-moiety, a cell expressing GPI-anchors at its surface, a GPI-anchored polypeptide, a cell expressing a GPI-anchored protein at its surface, or fragments thereof. A phage display library produced from the immunized rabbit is constructed and panned for the desired antibodies in accordance with methods well known in the art (such as, e.g., the methods disclosed in the various references recited herein).

55 [0087] Hybridoma cells secreting the monoclonal antibodies are also disclosed. The preferred hybridoma cells are genetically stable, secrete monoclonal antibodies described herein of the desired specificity, and can be expanded from deep-frozen cultures by thawing and propagation *in vitro* or as ascites *in vivo*.

5 [0088] There is also described a process is provided for the preparation of a hybridoma cell line secreting monoclonal antibodies against a GPI moiety or a GPI-anchored protein. In that process, a suitable mammal, for example a Balb/c mouse, is immunized with one or more polypeptides or antigenic fragments of, e.g., CD55 or CD14 or with one or more polypeptides or antigenic fragments derived from a CD55-expressing cell, the CD55-expressing cell itself, or an antigenic carrier containing a purified polypeptide as described. Similarly, the mammal can be immunized with a human GPI moiety, a fragment thereof, or cells that express the human GPI moiety, perhaps at a high amount. Antibody-producing cells of the immunized mammal are grown briefly in culture or fused with cells of a suitable myeloma cell line. The hybrid cells obtained in the fusion are cloned, and cell clones secreting the desired antibodies are selected. For example, spleen cells of Balb/c mice immunized with, e.g., a GPI-anchored protein or a GPI moiety are fused with cells of the myeloma cell line PAI or the myeloma cell line Sp2/0-Ag 14. The obtained hybrid cells are then screened for secretion of the desired antibodies and positive hybridoma cells are cloned.

10 [0089] Methods for preparing a hybridoma cell line include immunizing Balb/c mice by injecting subcutaneously and/or intraperitoneally an antigen of interest several times, e.g., four to six times, over several months, e.g., between two and four months. Spleen cells from the immunized mice are taken two to four days after the last injection and fused with cells of the myeloma cell line PAI in the presence of a fusion promoter, preferably polyethylene glycol. Preferably, the myeloma cells are fused with a three- to twenty-fold excess of spleen cells from the immunized mice in a solution containing about 30% to about 50% polyethylene glycol of a molecular weight around 4000. After the fusion, the cells are expanded in suitable culture media as described *supra*, supplemented with a selection medium, for example HAT medium, at regular intervals in order to prevent normal myeloma cells from overgrowing the desired hybridoma cells.

15 [0090] The antibodies and fragments thereof can be "chimeric." Chimeric antibodies and antigen-binding fragments thereof comprise portions from two or more different species (e.g., mouse and human). Chimeric antibodies can be produced with mouse variable regions of desired specificity spliced into human constant domain gene segments (for example, U.S. Patent No. 4,816,567). In this manner, non-human antibodies can be modified to make them more suitable for human clinical application (e.g., methods for detecting Type II PNH cells).

20 [0091] The monoclonal antibodies described herein include "humanized" forms of the non-human (e.g., mouse) antibodies. Humanized or CDR-grafted mAbs are particularly useful as therapeutic agents for humans because they are not cleared from the circulation as rapidly as mouse antibodies and do not typically provoke an adverse immune reaction. Generally, a humanized antibody has one or more amino acid residues introduced into it from a non-human source. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Methods of preparing humanized antibodies are generally well known in the art. For example, humanization can be essentially performed following the method of Winter and co-workers (see, e.g., Jones et al. (1986) Nature 321:522-525; Riechmann et al. (1988) Nature 332:323-327; and Verhoeyen et al. (1988) Science 239:1534-1536), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Also see, e.g., Staelens et al. (2006) Mol Immunol 43:1243-1257. In some embodiments, humanized forms of non-human (e.g., mouse) antibodies are human antibodies (recipient antibody) in which hypervariable (CDR) region residues of the recipient antibody are replaced by hypervariable region residues from a non-human species (donor antibody) such as a mouse, rat, rabbit, or non-human primate having the desired specificity, affinity, and binding capacity. In some instances, framework region residues of the human immunoglobulin are also replaced by corresponding non-human residues (so called "back mutations"). In addition, phage display libraries can be used to vary amino acids at chosen positions within the antibody sequence. The properties of a humanized antibody are also affected by the choice of the human framework. Furthermore, humanized and chimerized antibodies can be modified to comprise residues that are not found in the recipient antibody or in the donor antibody in order to further improve antibody properties, such as, for example, affinity or effector function.

25 [0092] Fully human antibodies are also described in the disclosure. The term "human antibody" includes antibodies having variable and constant regions (if present) derived from human germline immunoglobulin sequences. Human antibodies can include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis *in vitro* or by somatic mutation *in vivo*). However, the term "human antibody" does not include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences (i.e., humanized antibodies). Fully human or human antibodies may be derived from transgenic mice carrying human antibody genes (carrying the variable (V), diversity (D), joining (J), and constant (C) exons) or from human cells. For example, it is now possible to produce transgenic animals (e.g., mice) that are capable, upon immunization, of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production. (See, e.g., Jakobovits et al. (1993) Proc. Natl. Acad. Sci. USA 90:2551; Jakobovits et al. (1993) Nature 362:255-258; Bruggemann et al. (1993) Year in Immunol. 7:33; and Duchosal et al. (1992) Nature 355:258.) Transgenic mice strains can be engineered to contain gene sequences from unarranged human immunoglobulin genes. The human sequences may code for both the heavy and light chains of human antibodies and would function correctly in the mice, undergoing rearrangement to provide a wide antibody repertoire similar to that in humans. The transgenic mice can be immunized with the target protein (e.g., a GPI moiety

30
35
40
45
50
55

or a GPI-anchored protein such as CD55 or CD 14) to create a diverse array of specific antibodies and their encoding RNA. Nucleic acids encoding the antibody chain components of such antibodies may then be cloned from the animal into a display vector. Typically, separate populations of nucleic acids encoding heavy and light chain sequences are cloned, and the separate populations then recombined on insertion into the vector, such that any given copy of the vector receives a random combination of a heavy and a light chain. The vector is designed to express antibody chains so that they can be assembled and displayed on the outer surface of a display package containing the vector. For example, antibody chains can be expressed as fusion proteins with a phage coat protein from the outer surface of the phage. Thereafter, display packages can be screened for display of antibodies binding to a target.

[0093] In addition, human antibodies can be derived from phage-display libraries (Hoogenboom et al. (1991) J. Mol. Biol. 227:381; Marks et al. (1991) J. Mol. Biol., 222:581-597; and Vaughan et al. (1996) Nature Biotech 14:309 (1996)). Synthetic phage libraries can be created which use randomized combinations of synthetic human antibody V-regions. By selection on antigen fully human antibodies can be made in which the V-regions are very human-like in nature. See, e.g., U.S. Patent Nos. 6,794,132, 6,680,209,4,634,666, and Ostberg et al. (1983), Hybridoma 2:361-367.

[0094] For the generation of human antibodies, also see Mendez et al. (1998) Nature Genetics 15:146-156, Green and Jakobovits (1998) J. Exp. Med. 188:483-495.

[0095] Human antibodies are further discussed and delineated in U.S. Patent Nos.: 5,939,598; 6,673,986; 6,114,598; 6,075,181; 6,162,963; 6,150,584; 6,713,610; and 6,657,103 as well as U.S. Patent Publication Nos. 20030229905 A1, 20040010810 A1, US 20040093622 A1, 20060040363 A1, 20050054055 A1, 20050076395 A1, 20050287630 A1. See also International Publication Nos. WO 94/02602, WO 96/34096, and WO 98/24893, and European Patent No. EP 0 463 151 B1.

[0096] In an alternative approach, others, including GenPharm International, Inc., have utilized a "minilocus" approach. In the minilocus approach, an exogenous Ig locus is mimicked through the inclusion of pieces (individual genes) from the Ig locus. Thus, one or more V_H genes, one or more D_H genes, one or more J_H genes, a mu constant region, and a second constant region (preferably a gamma constant region) are formed into a construct for insertion into an animal. This approach is described in, e.g., U.S. Patent Nos.: 5,545,807; 5,545,806; 5,625,825; 5,625,126; 5,633,425; 5,661,016; 5,770,429; 5,789,650; and 5,814,318; 5,591,669; 5,612,205; 5,721,367; 5,789,215; 5,643,763; 5,569,825; 5,877,397; 6,300,129; 5,874,299; 6,255,458; and 7,041,871..

European Patent No. 0 546 073 B1, International Patent Publication Nos. WO 92/03918, WO 92/22645, WO 92/22647, WO 92/22670, WO 93/12227, WO 94/00569, WO 94/25585, WO 96/14436, WO 97/13852, and WO 98/24884.

See further Taylor et al. (1992) Nucleic Acids Res. 20: 6287; Chen et al. (1993) Int. Immunol. 5: 647; Tuailon et al. (1993) Proc. Natl. Acad. Sci. USA 90: 3720-4; Choi et al. (1993) Nature Genetics 4: 117; Lonberg et al. (1994) Nature 368: 856-859; Taylor et al. (1994) International Immunology 6: 579-591; Tuailon et al. (1995) J. Immunol. 154: 6453-65; Fishwild et al. (1996) Nature Biotechnology 14: 845; and Tuailon et al. (2000) Eur. J. Immunol. 10: 2998-3005.

[0097] There are described de-immunized antibodies (e.g., antibodies that bind to a human GPI moiety or to a GPI-anchored protein) or antigen-binding fragments thereof. De-immunized antibodies or antigen-binding fragments thereof may be modified so as to render the antibody or antigen-binding fragment thereof non-immunogenic, or less immunogenic, to a given species. De-immunization can be achieved by modifying the antibody or antigen-binding fragment thereof utilizing any of a variety of techniques known to those skilled in the art (see, e.g., PCT Publication Nos. WO 04/108158 and WO 00/34317). For example, an antibody or antigen-binding fragment thereof may be de-immunized by identifying potential T cell epitopes and/or B cell epitopes within the amino acid sequence of the antibody or antigen-binding fragment thereof and removing one or more of the potential T cell epitopes and/or B cell epitopes from the antibody or antigen-binding fragment thereof, for example, using recombinant techniques. The modified antibody or antigen-binding fragment thereof may then optionally be produced and tested to identify antibodies or antigen-binding fragments thereof that have retained one or more desired biological activities, such as, for example, binding affinity, but have reduced immunogenicity.

Methods for identifying potential T cell epitopes and/or B cell epitopes may be carried out using techniques known in the art, such as, for example, computational methods (see e.g., PCT Publication No. WO 02/069232), *in vitro* or *in silico* techniques, and biological assays or physical methods (such as, for example, determination of the binding of peptides to MHC molecules, determination of the binding of peptide:MHC complexes to the T cell receptors from the species to receive the antibody or antigen-binding fragment thereof, testing of the protein or peptide parts thereof using transgenic animals with the MHC molecules of the species to receive the antibody or antigen-binding fragment thereof, or testing with transgenic animals reconstituted with immune system cells from the species to receive the antibody or antigen-binding fragment thereof, etc.). The de-immunized antibodies described herein may include de-immunized antigen-binding fragments, Fab, Fv, scFv, Fab' and F(ab')₂, monoclonal antibodies, murine antibodies, engineered antibodies (such as, for example, chimeric, single chain, CDR-grafted, humanized, fully human antibodies, and artificially selected antibodies), synthetic antibodies and semi-synthetic antibodies.

[0098] A recombinant DNA comprising an insert coding for a heavy chain variable domain and/or for a light chain variable domain of an antibody-expressing cell line may be produced. The term DNA includes coding single stranded DNAs, double stranded DNAs consisting of said coding DNAs and of complementary DNAs thereto, or these comple-

mentary (single stranded) DNAs themselves.

[0099] Furthermore, a DNA encoding a heavy chain variable domain and/or a light chain variable domain of an antibody (e.g., an anti-GPI antibody or an anti-GPI-anchored protein antibody) can be enzymatically or chemically synthesized to contain the authentic DNA sequence coding for a heavy chain variable domain and/or for the light chain variable domain, or a mutant thereof. A mutant of the authentic DNA is a DNA encoding a heavy chain variable domain and/or a light chain variable domain of the above-mentioned antibodies in which one or more amino acids are deleted, inserted, or exchanged with one or more other amino acids. Preferably said modification(s) are outside the CDRs of the heavy chain variable domain and/or of the light chain variable domain of the antibody in humanization and expression optimization applications. The term mutant DNA also embraces silent mutants wherein one or more nucleotides are replaced by other nucleotides with the new codons coding for the same amino acid(s). The term mutant sequence also includes a degenerate sequence. Degenerate sequences are degenerate within the meaning of the genetic code in that an unlimited number of nucleotides are replaced by other nucleotides without resulting in a change of the amino acid sequence originally encoded. Such degenerate sequences may be useful due to their different restriction sites and/or frequency of particular codons which are preferred by the specific host, particularly *E. coli*, to obtain an optimal expression of the heavy chain murine variable domain and/or a light chain murine variable domain.

[0100] The term mutant is intended to include a DNA mutant obtained by *in vitro* mutagenesis of the authentic DNA according to methods known in the art.

[0101] For the assembly of complete tetrameric immunoglobulin molecules and the expression of chimeric antibodies, the recombinant DNA inserts coding for heavy and light chain variable domains are fused with the corresponding DNAs coding for heavy and light chain constant domains, then transferred into appropriate host cells, for example after incorporation into hybrid vectors.

[0102] Recombinant DNAs including an insert coding for a heavy chain murine variable domain of an antibody of interest fused to a human constant domain IgG, for example $\gamma 1$, $\gamma 2$, $\gamma 3$ or $\gamma 4$, in particular $\gamma 1$ or $\gamma 4$, may be used. Recombinant DNAs including an insert coding for a light chain murine variable domain of an antibody fused to a human constant domain κ or λ , preferably κ , are also provided.

[0103] Described herein are recombinant DNAs coding for a recombinant polypeptide wherein the heavy chain variable domain and the light chain variable domain are linked by way of a spacer group, optionally comprising a signal sequence facilitating the processing of the antibody in the host cell and/or a DNA sequence encoding a peptide facilitating the purification of the antibody and/or a cleavage site and/or a peptide spacer and/or an agent. The DNA coding for an agent is intended to be a DNA coding for the agent useful in diagnostic or therapeutic applications. Thus, agent molecules which are toxins or enzymes, especially enzymes capable of catalyzing the activation of prodrugs, are particularly indicated. The DNA encoding such an agent has the sequence of a naturally occurring enzyme or toxin encoding DNA, or a mutant thereof, and can be prepared by methods well known in the art.

[0104] Accordingly, the monoclonal antibodies or antigen-binding fragments of the disclosure can be naked antibodies or antigen-binding fragments that are not conjugated to other agents, for example, a therapeutic agent or detectable label. Alternatively, the monoclonal antibody or antigen-binding fragment can be conjugated to an agent such as, for example, a cytotoxic agent, a small molecule, a hormone, an enzyme, a growth factor, a cytokine, a ribozyme, a peptidomimetic, a chemical, a prodrug, a nucleic acid molecule including coding sequences (such as antisense, RNAi, gene-targeting constructs, etc.), or a detectable label (e.g., an NMR or X-ray contrasting agent, fluorescent molecule, etc.). An antibody or an antigen-binding fragment thereof (e.g., Fab, Fv, single-chain scFv, Fab', and F(ab')₂) may be linked to a molecule that increases the half-life of the antibody or antigen-binding fragment (see the section entitled "Conjugates").

[0105] Several possible vector systems are available for the expression of cloned heavy chain and light chain genes in mammalian cells. One class of vectors relies upon the integration of the desired gene sequences into the host cell genome. Cells which have stably integrated DNA can be selected by simultaneously introducing drug resistance genes such as *E. coli* gpt (Mulligan and Berg (1981) Proc. Natl. Acad. Sci. USA, 78:2072) or Tn5 neo (Southern and Berg (1982) Mol. Appl. Genet. 1:327). The selectable marker gene can be either linked to the DNA gene sequences to be expressed, or introduced into the same cell by co-transfection (Wigler et al. (1979) Cell 16:77). A second class of vectors utilizes DNA elements which confer autonomously replicating capabilities to an extrachromosomal plasmid. These vectors can be derived from animal viruses, such as bovine papillomavirus (Sarver et al. (1982) Proc. Natl. Acad. Sci. USA, 79:7147), polyoma virus (Deans et al. (1984) Proc. Natl. Acad. Sci. USA 81:1292), or SV40 virus (Lusky and Botchan (1981) Nature 293:79).

[0106] Since an immunoglobulin cDNA is comprised only of sequences representing the mature mRNA encoding an antibody protein, additional gene expression elements regulating transcription of the gene and processing of the RNA are required for the synthesis of immunoglobulin mRNA. These elements may include splice signals, transcription promoters, including inducible promoters, enhancers, and termination signals. cDNA expression vectors incorporating such elements include those described by Okayama and Berg (1983) Mol. Cell Biol. 3:280; Cepko et al. (1984) Cell 37:1053; and Kaufman (1985) Proc. Natl. Acad. Sci. USA 82:689.

[0107] As is evident from the disclosure, the anti-GPI moiety antibodies or anti-GPI-anchored protein antibodies can be used in methods for diagnosing disease (e.g., diagnosing PNH or an increased risk of developing thrombocytopenia), monitoring of disease progression, and the selection of appropriate therapies, including combination therapies, for treating PNH, thrombocytopenia, or thrombosis in a subject.

[0108] In the present disclosure, bispecific antibodies are contemplated. Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for a GPI moiety or a GPI-anchored protein on a cell (such as, e.g., a white blood cell or a red blood cell), the other one is for any other antigen, and preferably for a cell-surface protein or receptor or receptor subunit.

[0109] Methods for making bispecific antibodies are within the purview of those skilled in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities (Milstein and Cuello (1983) *Nature* 305:537-539). Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, including at least part of the hinge, C_H2, and C_H3 regions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of illustrative currently known methods for generating bispecific antibodies see, e.g., Suresh et al. (1986) *Methods in Enzymology* 121:210; PCT Publication No. WO 96/27011; Brennan et al. (1985) *Science* 229:81; Shalaby et al., *J. Exp. Med.* (1992) 175:217-225; Kostelny et al. (1992) *J. Immunol.* 148(5):1547-1553; Hollinger et al. (1993) *Proc. Natl. Acad. Sci. USA* 90:6444-6448; Gruber et al. (1994) *J. Immunol.* 152:5368; and Tutt et al. (1991) *J. Immunol.* 147:60. Bispecific antibodies also include cross-linked or heteroconjugate antibodies. Heteroconjugate antibodies may be made using any convenient cross-linking methods. Suitable cross-linking agents are well known in the art, and are disclosed in U.S. Pat. No. 4,676,980, along with a number of cross-linking techniques.

[0110] Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. (See, e.g., Kostelny et al. (1992) *J. Immunol.* 148(5):1547-1553). The leucine zipper peptides from the Fos and Jun proteins may be linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers may be reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The "diabody" technology described by Hollinger et al. (1993) *Proc. Natl. Acad. Sci. USA* 90:6444-6448 has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (VH) connected to a light-chain variable domain (VL) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the VH and VL domains of one fragment are forced to pair with the complementary VL and VH domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (scFv) dimers has also been reported. (See, e.g., Gruber et al. (1994) *J. Immunol.* 152:5368.) Alternatively, the antibodies can be "linear antibodies" as described in, e.g., Zapata et al. (1995) *Protein Eng.* 8(10):1057-1062. Briefly, these antibodies comprise a pair of tandem Fd segments (V_H-C_H1-V_H-C_H1) which form a pair of antigen binding regions. Linear antibodies can be bispecific or monospecific.

Conjugates

[0111] A reagent described herein (e.g., a non-lytic aerolysin polypeptide or an antibody that binds to a GPI moiety or a GPI-anchored protein) can be conjugated to a heterologous moiety. The heterologous moiety can be, e.g., a heterologous protein (see above), a therapeutic agent (e.g., a toxin or a drug), or a detectable label such as, but not limited to, a radioactive label, an enzymatic label, a fluorescent label, or a luminescent label. Suitable radioactive labels include, e.g., ³²P, ³³P, ¹⁴C, ¹²⁵I, ¹³¹I, ³⁵S, and ³H. Suitable fluorescent labels include, without limitation, fluorescein, fluorescein isothiocyanate (FITC), Alexa Fluor® 488, Alexa Fluor® 647, GFP, DyLight 488, phycoerythrin (PE), propidium iodide (PI), PerCP, PE-Alexa Fluor® 700, Cy5, allophycocyanin, Cy7, and PE-Alexa Fluor® 750. Luminescent labels include, e.g., any of a variety of luminescent lanthanide (e.g., europium or terbium) chelates. For example, suitable europium chelates include the europium chelate of diethylene triamine pentaacetic acid (DTPA). Enzymatic labels include, e.g., alkaline phosphatase, CAT, luciferase, and horseradish peroxidase.

[0112] Suitable methods for conjugating a heterologous moiety to the reagent are well-known in the art of protein chemistry. For example, two proteins can be cross-linked using any of a number of known chemical cross linkers. Examples of such cross linkers are those which link two amino acid residues via a linkage that includes a "hindered" disulfide bond. In these linkages, a disulfide bond within the cross-linking unit is protected (by hindering groups on either side of the disulfide bond) from reduction by the action, for example, of reduced glutathione or the enzyme disulfide reductase. One suitable reagent, 4-succinimidylloxycarbonyl- α -methyl- α (2-pyridyl)dithio) toluene (SMPT), forms such a

linkage between two proteins utilizing a terminal lysine on one of the proteins and a terminal cysteine on the other. Heterobifunctional reagents that cross-link by a different coupling moiety on each protein can also be used. Other useful cross-linkers include, without limitation, reagents which link two amino groups (e.g., N-5-azido-2-nitrobenzoyloxysuccinimide), two sulfhydryl groups (e.g., 1,4-bis-maleimidobutane) an amino group and a sulfhydryl group (e.g., m-maleimidobenzoyl-N-hydroxysuccinimide ester), an amino group and a carboxyl group (e.g., 4-[p-azidosalicylamido] butylamine), and an amino group and a guanidinium group that is present in the side chain of arginine (e.g., p-azidophenyl glyoxal monohydrate).

[0113] Radioactive labels can be conjugated to the reagent by covalent or noncovalent (e.g., ionic or hydrophobic) bonds. They can be bound to any part of the protein provided that the conjugation does not interfere with the ability of the reagent to bind to a GPI moiety or to a GPI-anchored protein. Where the reagent is a protein, the radioactive label can be directly conjugated to the amino acid backbone of the reagent. Alternatively, the radioactive label can be included as part of a larger molecule (e.g., ¹²⁵I in meta-[¹²⁵I]iodophenyl-N-hydroxysuccinimide ([¹²⁵I]mIPNHS) which binds to free amino groups to form meta-iodophenyl (mIP) derivatives of relevant proteins (see, e.g., Rogers et al. (1997) J. Nucl. Med. 38:1221-1229) or chelate (e.g., to DOTA or DTPA) which is in turn bound to the protein backbone. Methods of conjugating the radioactive labels or larger molecules/chelates containing them to the reagents described herein are also known in the art. Such methods involve incubating the reagent with the radioactive label under conditions (e.g., pH, salt concentration, and/or temperature) that facilitate binding of the radioactive label or chelate to the reagent (see, e.g. U.S. Patent No. 6,001,329).

[0114] Methods for conjugating a fluorescent label (sometimes referred to as a "fluorophore") to a reagent (e.g., a non-lytic aerolysin protein or an antibody) are known in the art of protein chemistry. For example, fluorophores can be conjugated to free amino groups (e.g., of lysines) or sulfhydryl groups (e.g., cysteines) of proteins using succinimidyl (NHS) ester or TFP ester moieties attached to the fluorophores. In some embodiments, the fluorophores can be conjugated to a heterobifunctional crosslinker moiety such as sulfo-SMCC. Suitable conjugation methods involve incubating the reagent with the fluorophore under conditions that facilitate binding of the fluorophore to the reagent. See, e.g., Welch and Redvanly (2003) "Handbook of Radiopharmaceuticals: Radiochemistry and Applications," John Wiley and Sons (ISBN: 0471495603). A variety of kits are commercially available for use in conjugating a fluorophore to a protein, e.g., the Alexa Fluor® 488 Protein Labeling Kit and the Alexa Fluor® 647 Protein Labeling Kit (Molecular Probes, Invitrogen™).

[0115] The fluorophore can be conjugated to a reagent at 1-2 mol dye per mol of protein.

[0116] The reagents described herein (e.g., an aerolysin protein or an antibody that binds to a GPI moiety or a GPI-anchored protein) can be modified, e.g., with a moiety that improves the stabilization and/or retention of the antibodies themselves in circulation, e.g., in blood, serum, or other tissues. For example, a reagent described herein can be PEGylated as described in, e.g., Lee et al. (1999) Bioconjug. Chem 10(6): 973-8; Kinstler et al. (2002) Advanced Drug Deliveries Reviews 54:477-485; and Roberts et al. (2002) Advanced Drug Delivery Reviews 54:459-476. The stabilization moiety can improve the stability, or retention of, the reagent in a subject's body (e.g., blood or tissue) by at least 1.5 (e.g., at least 2, 5, 10, 15, 20, 25, 30, 40, or 50 or more) fold.

Biological Samples and Sample Collection

[0117] Suitable biological samples for use in the methods described herein include any biological fluid, population of cells, or tissue or fraction thereof, which includes one or more white blood cells and/or one or more red blood cells. A biological sample can be, for example, a specimen obtained from a subject (e.g., a mammal such as a human) or can be derived from such a subject. For example, a sample can be a tissue section obtained by biopsy, or cells that are placed in or adapted to tissue culture. A biological sample can also be a biological fluid such as urine, whole blood or a fraction thereof (e.g., plasma), saliva, semen, sputum, cerebral spinal fluid, tears, or mucus. A biological sample can be further fractionated, if desired, to a fraction containing particular cell types. For example, a whole blood sample can be fractionated into serum or into fractions containing particular types of blood cells such as red blood cells or white blood cells (leukocytes). If desired, a biological sample can be a combination of different biological samples from a subject such as a combination of a tissue and fluid sample.

[0118] The biological samples can be obtained from a subject, e.g., a subject having, suspected of having, or at risk of developing, paroxysmal nocturnal hemoglobinuria (PNH). Any suitable methods for obtaining the biological samples can be employed, although exemplary methods include, e.g., phlebotomy, swab (e.g., buccal swab), lavage, or fine needle aspirate biopsy procedure. Non-limiting examples of tissues susceptible to fine needle aspiration include lymph node, lung, thyroid, breast, and liver. Biological samples can also be obtained from bone marrow. Samples can also be collected, e.g., by microdissection (e.g., laser capture microdissection (LCM) or laser microdissection (LMD)), bladder wash, smear (PAP smear), or ductal lavage.

[0119] Methods for obtaining and/or storing samples that preserve the activity or integrity of cells in the biological sample are well known to those skilled in the art.

For example, a biological sample can be further contacted with one or more additional agents such as appropriate buffers and/or inhibitors, including protease inhibitors, the agents meant to preserve or minimize changes in the cells (e.g., changes in osmolarity or pH) or denaturation of cell surface proteins (e.g., GPI-linked proteins) or GPI moieties on the surface of the cells. Such inhibitors include, for example, chelators such as ethylenediamine tetraacetic acid (EDTA), ethylene glycol tetraacetic acid (EGTA), protease inhibitors such as phenylmethylsulfonyl fluoride (PMSF), aprotinin, and leupeptin. Appropriate buffers and conditions for storing or otherwise manipulating whole cells are described in, e.g., Pollard and Walker (1997), "Basic Cell Culture Protocols," volume 75 of Methods in Molecular Biology, Humana Press; Masters (2000) "Animal cell culture: a practical approach," volume 232 of Practical approach series, Oxford University Press; and Jones (1996) "Human cell culture protocols," volume 2 of Methods in molecular medicine, Humana Press."

[0120] A sample also can be processed to eliminate or minimize the presence of interfering substances. For example, a biological sample can be fractionated or purified to remove one or more materials (e.g., cells) that are not of interest. Methods of fractionating or purifying a biological sample include, but are not limited to, flow cytometry, fluorescence activated cell sorting, and sedimentation.

Diagnostic and Therapeutic Methods

[0121] As noted above and elaborated on in the working examples, the inventors have discovered a clinical relationship between the presence or amount of PNH Type II hematopoietic cells (e.g., Type II white blood cells and/or Type II red blood cells) and thrombocytopenia in a patient. For example, the inventors have determined that a patient with a PNH Type II white blood cell population of at least 1.2 (e.g., at least 1.2, 1.5, 2, 3, 5, 7, 9, 10, 12, 15, 17, 20, 22, 25, 27, 30, 32, 35, 37, 40, 42, 45, 47, 50, 52, 55, 57, 60, 62, 65, or 65.3 or more) % as compared to the total white blood cells of the same histological type (the same lineage) in the biological sample tested is much more likely to be thrombocytopenic than a patient who does not have a detectable PNH Type II white blood cell population or a patient with a PNH Type II white blood cell population lower than 1.2%. Patient samples with PNH Type II granulocyte populations had similar peripheral white blood cell counts, peripheral red blood cell counts, absolute neutrophil counts, and hemoglobin (Hgb) levels, compared to patient samples without detectable Type II granulocyte populations, indicating that differences in platelet counts are likely not due to differences in underlying bone marrow production. In other words, the decreased platelet counts in patients with detectable PNH Type II granulocyte clones may be due to increased terminal complement-mediated platelet consumption or destruction, which can be associated with thrombosis, the leading cause of death among PNH patients. See, e.g., Franchini (2006) Hematology 11(3):139-146. Accordingly, the present disclosure features methods for using information related to the percentage of PNH Type II white blood cells in a patient sample for determining whether the patient is at an increased risk of developing thrombocytopenia and/or thrombosis. Similarly, the inventors have determined that a patient with a PNH Type II RBC population of at least 0.02 (e.g., at least 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 71, 71.3, or 75 or more) % is much more likely to be thrombocytopenic than a patient who does not have a detectable PNH Type II RBC population or a patient with a PNH Type II RBC population lower than 0.02%. Thus, the present disclosure also features methods for using information related to the PNH Type II RBC clone size in a patient for determining whether the patient is at risk of developing thrombocytopenia and/or thrombosis.

[0122] The following methods can be employed to detect the presence, or to determine the percentage, of PNH Type II hematopoietic cells (e.g., Type II PNH white blood cells) as compared to the total amount of cells of the same histological type (same lineage) in a biological sample from the patient. Where a plurality of white blood cells are interrogated, the methods may be useful in allowing a practitioner to distinguish between populations of PNH Type I, Type II, and Type III white blood cells of the same histological type (same lineage) in order to accurately determine the size of the total abnormal PNH population (i.e., Type II plus Type III cells) as compared to the total number of white blood cells of the same histological type in the plurality (and/or allow the practitioner to determine the percentage of PNH Type II white blood cells in the plurality). First, a population of cells (e.g., white blood cells, red blood cells, or a combination of white and red blood cells) is contacted with a reagent that binds to: (i) a GPI moiety or (ii) a GPI-linked protein for a period of time and under conditions that allow for the binding of the reagent to the GPI moiety or GPI-linked protein if present on the surface of cells present in the sample. The population of cells can be present in a biological sample (e.g., a whole blood sample; see the section entitled "Biological Samples and Sample Collection"), e.g., a biological sample obtained from a patient. For example, cells present in a whole blood sample from a patient can be contacted with an aerolysin protein (e.g., a non-lytic form of aerolysin) or an antibody that binds to a GPI moiety or a GPI-anchored protein such as CD59. See, e.g., Hall and Rosse (1996) Blood 87(12):5332-5340 and U.S. Patent No. 6,593,095. At least a portion of the cells (e.g., white blood cells or RBCs) contacted with the reagent can be distinguished based on the amount of reagent bound to the surface of the cells. For example, where a detectably-labeled reagent was used, the amount of

reagent bound to the surface can be determined as a function of the total amount of signal produced from detectably labeled reagent bound to the surface of the cell. As described above, the amount of binding of the reagent to the cell reflects the amount of expression of GPI moieties and/or GPI-anchored proteins, which are indicative of whether cells are PNH Type III cells (little or no expression of GPI and GPI-anchored proteins), normal cells (Type I cells; having a relatively high level of expression of GPI and GPI-anchored proteins as compared to the Type III cells), and PNH Type II cells (having an intermediate level of expression of GPI and GPI-anchored proteins as compared to Type I cells and Type III cells). The distinguishing or interrogating process can involve, e.g., flow cytometry.

[0123] The methods may be used to detect the amount of binding of a reagent to RBCs from a patient sample. The methods can be used to detect the amount of binding of a reagent to white blood cells from a patient sample. White blood cells that are particularly amenable to evaluation in the diagnostic methods described herein include, e.g., granulocytes and monocytes (e.g., macrophages).

[0124] The samples can be from patients who have, are suspected of having, or at risk for developing paroxysmal nocturnal hemoglobinuria (PNH). The patients may have one or more symptoms including, e.g, Coombs negative intravascular hemolysis, elevated LDH levels, recurrent iron deficiency anemia, thrombosis in unusual sites, episodic dysphagia, or abdominal pain.

[0125] To aid in the identification of normal cells or PNH cells, a set of control cell populations can also be subjected to the detection method. The control populations can be evaluated before, concurrently, or after the evaluation of the cell population of interest. As discussed in more detail below, a practitioner can choose to subject a control population of cells known to be PNH Type II cells, a control population of cells known to be PNH Type III cells, and/or a control population of cells known to be normal or Type I cells to the methods to determine the typical amount, or average amount, of binding of the reagent used to a particular type of cell. This control information can be used to classify or identify cells (e.g., white blood cells or red blood cells) of interest as normal cells, PNH Type II cells, and/or PNH Type III cells.

[0126] Depending on the particular composition of the cell population within the biological sample, at least some cells of the population can be distinguished from other cells based on a high amount of bound reagent, a low amount of bound reagent, or an intermediate level of bound reagent. In some cases, only cells with a high amount of bound reagent will be present (for example, cells from a healthy patient or a patient who does not have PNH). In some cases, a larger percentage of cells will have little, or no, reagent bound to their surface (for example, white blood cells or RBCs from a PNH patient having a high percentage of PNH Type III cells).

A population of cells contacted with the reagent can be classified into high, low, and intermediate categories based on the amount of reagent bound to the cells.

[0127] One or more cells (e.g., one or more distinguished or interrogated cells) can be classified based on the amount of reagent bound to their cell surface. As exemplified in the working examples and depicted in Fig. 1, individual cells in a population can be readily classified as highly reagent bound, low or poorly reagent bound, and intermediately reagent bound using flow cytometry methods. For example, white blood cells obtained from a patient with PNH are contacted with two different reagents: a first reagent that binds to a GPI moiety (e.g., a detectably-labeled, non-lytic aerolysin protein) and a second reagent that binds to a GPI-anchored protein (e.g., a detectably-labeled antibody that binds to human CD24). The first reagent and second reagent are labeled with different detectable labels. The contacted cells are then subjected to flow cytometry. An artisan skilled in the art of flow cytometry would be readily able to use the methods to distinguish between cells based on the amount of binding of each reagent to the cells. See, e.g., Macey (2007) "Flow Cytometry: principles and applications," Humana Press (ISBN: 1588296911) and Brodsky et al. (2000) *Am J Clin Pathol* 114:459-466. As shown in Fig. 1, the flow cytometry methods can readily be used to classify granulocytes obtained from a PNH patient as having a high amount of binding of each of the reagents (cell population at upper right; normal or Type I cells), a low amount of binding of each reagent (cell population at lower left; Type III cells), and an intermediate amount of binding of each reagent (cell population at bottom center; Type II cells).

[0128] The classification of a cell can be performed by comparing the amount of the reagent bound to the cell to a control amount (e.g., a control amount of binding of the reagent to PNH Type I cells, PNH Type II cells, and/or PNH Type III cells). The control amount of binding of the reagent to PNH Type I cells can be based on, e.g., the average amount of observed binding of the reagent to cells of the same histological type obtained from one or more (e.g., two, three, four, five, six, seven, eight, nine, 10, 15, 20, 25, 30, 35, or 40 or more) healthy individuals. The control amount of binding of the reagent to PNH Type III cells can be based on, e.g., the average amount of binding observed to cells of the same type obtained from one or more (e.g., two, three, four, five, six, seven, eight, nine, 10, 15, 20, 25, 30, 35, or 40 or more) patients with PNH. The control amount of binding of the reagent to PNH Type II cells can be based on, e.g., the average amount of binding observed to cells of the same type obtained from one or more (e.g., two, three, four, five, six, seven, eight, nine, 10, 15, 20, 25, 30, 35, or 40 or more) patients with PNH and having a detectable population of PNH Type II cells of the same histological type (same lineage). For example, to classify a white blood cell of interest based on the amount of reagent bound to the surface of the cell, a practitioner can compare the amount of reagent bound to the cell with the typical amount, or average amount, of reagent bound to a white blood cell known to be a PNH Type I white blood, a white blood cell known to be a PNH Type II white blood cell, and/or a white blood cell known to be

a PNH Type III white blood cell.

[0129] The distinguishing or classifying of a cell (e.g., a white blood cell or RBC) of interest can be performed by determining whether the amount of a reagent bound to the cell falls within a predetermined range indicative of PNH Type I cells, PNH Type II cells, or PNH Type III cells of the same histological type.

[0130] The distinguishing or classifying of a hematopoietic cell of interest can include determining if the amount of reagent bound to the surface of the cell falls above or below a predetermined cut-off value. A cut-off value is typically the amount of reagent bound to the surface of a cell (or the amount of signal detected from a cell) above or below which is considered indicative of a certain class of cells, namely PNH Type I cells, PNH Type II cells, or PNH Type III cells.

[0131] Some cut-off values are not absolute in that diagnostic correlations (e.g., an amount of reagent bound to the surface of the cell and likelihood that the cell is a PNH Type II cell) can still remain significant over a range of values on either side of the cutoff. It is understood that refinements in optimal cut-off values could be determined depending on the quality of reagents used, the sophistication of statistical methods and detection device (e.g., flow cytometry) used, and on the number and source of samples interrogated. Therefore, cut-off values can be adjusted up or down, on the basis of periodic re-evaluations or changes in methodology or sample distribution.

[0132] As used herein, "thrombocytopenia" refers to a condition in which a patient has a platelet count of less than 200,000 (e.g., less than 150,000; less than 140,000; less than 130,000; less than 120,000; less than 110,000; less than 100,000; or less than 90,000) platelets per μL of blood. A patient with thrombocytopenia may have a platelet count of less than 100,000 platelets per μL of blood.

[0133] As described above, information related to the percentage of PNH Type II cells can be used in methods for determining whether a patient is at increased risk for developing thrombosis. The information related to the percentage of PNH Type II cells (e.g., Type II white blood cells and/or Type II red blood cells) in a biological sample from a patient can be communicated (e.g., electronic or printed form) to a medical practitioner to be used by the practitioner for selecting an appropriate therapeutic regimen for the patient. Based on a PNH Type II white blood cell population of at least 1.2 (e.g., at least 1.2, 1.5, 2, 3, 5, 7, 9, 10, 12, 15, 17, 20, 22, 25, 27, 30, 32, 35, 37, 40, 42, 45, 47, 50, 52, 55, 57, 60, 62, 65, or 65.3 or more) %, as compared to the total number of white blood cells of the same histological type in the biological sample tested, the practitioner may determine that the patient is at risk of developing thrombocytopenia, or may likely be thrombocytopenic. Likewise, a patient with a PNH Type II RBC population of at least 0.02 (e.g., at least 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 71, 71.3, or 75 or more) % of the total RBC in the biological sample tested is much more likely to be thrombocytopenic than a patient who does not have a detectable PNH Type II RBC population or a patient with a PNH Type II RBC population lower than 0.02%. A patient with a PNH Type II white blood cell population of at least 1.2% or a PNH Type II red blood cell population of at least 0.02% can be, e.g., at least 1.5 (e.g., 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 15, 20, 30, or even 40 or more) times as likely to develop a thrombus than a normal individual or a patient that does not have that percentage of PNH Type II cells.

[0134] The medical practitioner may request additional tests to determine the platelet counts in the patient. Methods for determining platelet counts in a blood-derived sample from a subject are well known in the art of medicine and described in, e.g., Sallah et al. (1998) *Postgraduate Medicine* 103:209-210; Kottke-Marchant (1994) *Hematol Oncol Clin North Am.* 8:809-853; Redei et al. (1995) *J Crit Illn* 10:133-137; Butkiewicz et al. (2006) *Thrombosis Research* 118(2): 199-204; Tomita et al. (2000) *Am J Hematol* 63(3):131-135; and Schrezenmeier et al. (1998) *Br J Haematol* 100(3):571-576.

[0135] If the patient is determined by the medical practitioner to be thrombocytopenic or to likely be thrombocytopenic, the practitioner may select, prescribe, or administer to the patient an anti-thrombocytopenic therapy. The anti-thrombocytopenic therapy can be, e.g., a corticosteroid, platelet transfusion, a splenectomy, or a platelet production-stimulating agent. The platelet production-stimulating agent can be, e.g., thrombopoietin (TPO) or a thrombopoietin mimetic. See, e.g., Kuter and Begley (2002) *Blood* 100:3457-3469; Li et al. (2001) *Blood* 98:3241-3248; and Vadhan-Raj et al. (2000) *Ann Intern Med* 132:364-368. A TPO mimetic peptide can have the amino acid sequence depicted in Figure 5 of U.S. Patent Application Publication No. 20030049683.

[0136] If the percentage of PNH Type II white blood cells in a biological sample from a patient is about 1.2%, the medical practitioner may also determine that the patient is at an increased risk for developing thrombosis. The medical practitioner may then select for the patient an appropriate anti-thrombotic therapy. For example, the practitioner may select, prescribe, or administer to the patient an anticoagulant or thrombolytic agent. The anticoagulant can be, e.g., coumadin, heparin, or derivatives thereof. The thrombolytic agent can be, e.g., a tissue plasminogen activator (e.g., Retavase™, Rapilysin™), streptokinase, or a urokinase-type plasminogen activator.

[0137] A patient determined to have a PNH Type II white blood cell population of greater than or equal to 1.2% or a PNH Type II red blood cell population of greater than or equal to 0.02% can be diagnosed as having PNH. A patient diagnosed with having PNH or a previously diagnosed PNH patient who is determined to have a PNH Type II white

blood cell population greater than or equal to 1.2% or a PNH Type II red blood cell population that is greater than or equal to 0.02% can be prescribed and/or treated with a complement inhibitor.

[0138] Any compounds which bind to or otherwise block the generation and/or activity of any of the human complement components may be utilized in accordance with the present disclosure. For example, an inhibitor of complement can be, e.g., a small molecule, a nucleic acid or nucleic acid analog, a peptidomimetic, or a macromolecule that is not a nucleic acid or a protein. These agents include, but are not limited to, small organic molecules, RNA aptamers, L-RNA aptamers, Spiegelmers, antisense compounds, double stranded RNA, small interfering RNA, locked nucleic acid inhibitors, and peptide nucleic acid inhibitors. A complement inhibitor may be a protein or protein fragment.

[0139] Antibodies specific to a human complement component may be useful herein. Some compounds include antibodies directed against complement components C1, C2, C3, C4, C5 (or a fragment thereof; see below), C6, C7, C8, C9, Factor D, Factor B, Factor P, MBL, MASP-1, and MASP-2, thus preventing the generation of the anaphylatoxic activity associated with C5a and/or preventing the assembly of the membrane attack complex associated with C5b.

[0140] Also useful in the present methods are naturally occurring or soluble forms of complement inhibitory compounds such as CR1, LEX-CR1, MCP, DAF, CD59, Factor H, cobra venom factor, FUT-175, complestatin, and K76 COOH. Other compounds which may be utilized to bind to or otherwise block the generation and/or activity of any of the human complement components include, but are not limited to, proteins, protein fragments, peptides, small molecules, RNA aptamers including ARC187 (which is commercially available from Archemix Corporation, Cambridge, MA), L-RNA aptamers, spiegelmers, antisense compounds, serine protease inhibitors, molecules which may be utilized in RNA interference (RNAi) such as double stranded RNA including small interfering RNA (siRNA), locked nucleic acid (LNA) inhibitors, peptide nucleic acid (PNA) inhibitors, etc.

[0141] The complement inhibitor may inhibit the activation of complement. For example, the complement inhibitor can bind to and inhibit the complement activation activity of C1 (e.g., C1q, C1r, or C1s) or the complement inhibitor can bind to and inhibit (e.g., inhibit cleavage of) C2, C3, or C4.

The inhibitor may inhibit formation or assembly of the C3 convertase and/or C5 convertase of the alternative and/or classical pathways of complement.

The complement inhibitor may inhibit terminal complement formation, e.g., formation of the C5b-9 membrane attack complex. For example, an antibody complement inhibitor may include an anti-C5 antibody. Such anti-C5 antibodies may directly interact with C5 and/or C5b, so as to inhibit the formation of and/or physiologic function of C5b. Exemplary anti-C5 antibodies include, e.g., eculizumab (Soliris®; Alexion Pharmaceuticals, Inc., Cheshire, CT; see, e.g., Kaplan (2002) *Curr Opin Investig Drugs* 3(7):1017-23; Hill (2005) *Clin Adv Hematol Oncol* 3(11):849-50; and Rother et al. (2007) *Nature Biotechnology* 25(11):1256-1488) and pexelizumab (Alexion Pharmaceuticals, Inc., Cheshire, CT; see, e.g., Whiss (2002) *Curr Opin Investig Drugs* 3(6):870-7; Patel et al. (2005) *Drugs Today (Barc)* 41(3):165-70; and Thomas et al. (1996) *Mol Immunol.* 33(17-18):1389-401).

[0142] Methods for administering an appropriate anti-thrombotic therapy and/or an anti-thrombocytopenic therapy to a patient in need thereof are well known in the art of medicine.

[0143] Methods for determining whether a patient is at an increased risk for developing thrombocytopenia or thrombosis can be aided by computer. For example, the methods can include receiving data including a medical profile of a PNH patient, the profile comprising information on the percentage of PNH Type II white blood cells of the total white blood cells of the same histological type (same lineage) in a biological sample from the patient; and processing at least the portion of the data containing the information to determine whether the patient is at an increased risk for developing thrombosis. In another example, the methods can include providing information on the percentage of PNH Type II white blood cells of the total white blood cells of the same histological type in a biological sample from the patient; inputting the information into a computer; and calculating a parameter indicating whether the patient is at an increased risk for thrombosis using the computer and the input information. The relative risk of the patient for developing thrombocytopenia or thrombosis can be output by the computer in print and/or can be stored on a computer-readable medium.

Kits

[0144] Also featured herein are kits for use in: determining whether a biological sample from a patient contains a PNH Type II white blood cell population and/or determining if a patient is at increased risk for developing thrombocytopenia or thrombosis. The kits can include, e.g., one or more of detectably-labeled conjugates selected from: an aerolysin conjugate (e.g., a non-lytic variant aerolysin protein conjugate) or conjugates of antibodies that bind to GPI-anchored proteins. The kits can also include a control sample containing a GPI expressing cell or GPI bound particle; and optionally, instructions for detecting the presence of a GPI expressing cell. The kits can also include one or more means for obtaining a biological sample (e.g., a blood sample) from a human and/or any of the kit components described above.

[0145] The following examples are intended to illustrate, not limit, the invention.

ExamplesExample 1. Materials and Methods

5 **[0146]** A total of 2,921 patient peripheral blood samples were obtained to test for the presence of PNH Type II cells and PNH Type III cells. The blood samples were drawn into sterile vials containing EDTA.

10 **[0147]** To determine the percentage of normal white blood cells (Type I cells), PNH Type II, and PNH Type III white blood cells present in each of the patient samples, the peripheral blood was mixed and stained with one or more of the following conjugates: a non-lytic aerolysin variant protein conjugated to AlexaFluor® 488 (Protox Biotech FL2-S), an anti-CD24 antibody conjugated to phycoerythrin (PE) (Beckman Coulter Clone ALB9), an anti-CD15 antibody conjugated to PC5 (Clone 80H5), and an anti-CD45 antibody conjugated to PC7 (Clone J.33). After incubation of the blood with one or more of the above reagents for 15-30 minutes at room temperature, the blood was lysed with Immunoprep™ (Beckman Coulter) and washed twice with PBA buffer (phosphate-buffered saline, 1% bovine serum albumin, and 10 mM NaN₃). Cells are then re-suspended in PBA buffer and analyzed using the FC 500 Flow Cytometer (Beckman Coulter). If a PNH Type II or Type III granulocyte population was identified, the monocytes were also interrogated for Type II or Type III population using patient blood contacted with one or more of the following conjugates: a non-lytic aerolysin variant protein conjugated to AlexaFluor® 488 (Protox Biotech FL2-S), an antibody that binds to CD33 conjugated to phycoerythrin (PE) (Clone D3HL60.251), an antibody that binds to CD14 conjugated to ECD (Clone RMO52), an antibody that binds to CD64 conjugated to PC5 (Clone 22), and an antibody that binds to CD45 conjugated to PC7 (Clone J.33), which allowed for lineage-specific gating on monocytes.

20 **[0148]** To determine the percentage of normal red blood cells (Type I cells), PNH Type II, and PNH Type III red blood cells 20 µl of peripheral blood in EDTA was placed in 3 mL of phosphate buffered saline (PBS) and mixed thoroughly. 50 µl of diluted patient blood was contacted with one or more of the following conjugates: an anti-CD235a antibody conjugated to FITC (Beckman Coulter clone 11E4B-7-6 / KC16) and an anti-CD59 antibody conjugated to PE (Invitrogen Clone MEM-43). The blood and conjugates were incubated at room temperature in the dark for one hour while vortexing every 15 minutes. After the one hour incubation, the blood was washed twice with PBS, resuspended in PBS, and analyzed on an FC 500 Flow Cytometer (Beckman Coulter).

Example 2.

30 **[0149]** Whole blood samples from 2,921 patients, which samples were submitted for diagnostic testing for PNH, were analyzed using a high-sensitivity flow cytometry-based assay to detect the expression level of GPI and GPI-anchored proteins on white blood cells (particularly granulocytes) to thereby determine the Type I, PNH Type II, and PNH Type III white blood cell (granulocyte) populations in each of the samples. The assay was also used to detect the Type I, PNH Type II, and PNH Type III red blood cell populations in each of the patient samples. The methods employed a fluorescently-labeled non-lytic aerolysin protein variant along with antibodies to specific GPI-anchored lineage-specific protein antigens. An exemplary flow-cytometry analysis of one patient sample is depicted in Fig. 1. Cells from a whole blood sample were contacted with the fluorescently-labeled aerolysin reagent (Alexa Fluor) and a phycoerythrin (PE)-labeled antibody that binds to the GPI-anchored protein CD24. The cells of the whole blood sample were subjected to flow cytometry analysis and the granulocytes therein displayed based on the amount of signal detected from each reagent bound to the surface of the granulocytes. As shown in Fig. 1, granulocytes with the highest amount of signal detected from the AlexaFluor and PE labels (upper right; Type I cells) were separated from populations of granulocytes having a very low or absent signal (lower left; Type III granulocytes) and granulocytes producing an intermediate amount of signal (middle population; Type II granulocytes).

45 **[0150]** The PNH red blood cell populations were interrogated using two reagents: a detectably-labeled antibody that binds to CD235 and a detectably-labeled reagent that binds to CD59. The PNH white blood cell populations were interrogated using the detectably-labeled aerolysin protein and several antibodies to GPI-anchored lineage-specific cell surface proteins including CD24, CD14, CD16, CD66b, and CD55.

50 **[0151]** 216 of the patient samples had a detectable PNH Type III granulocyte population that was > 0.01% of the total number of granulocytes in the sample and an absolute count of at least 50 PNH Type III granulocytes. Clinical information related to several parameters (e.g., hemoglobin levels, LDH levels, and platelet counts) was available for 162 of these patients (see Table 1).

Table 1. Clinical Features of Patients with a Detectable PNH Type III or II granulocyte population (where clinical data were available.)

	Cases with Type II granulocytes (N=19)	Cases without Type II granulocytes (N=143)	P-value Wilcoxin	
5	Median (range) Total PNH granulocyte population (%)	87.20 (9.2-99.5)	11.40 (0.01-99.9)	<0.01
10	Median (range) PNH Type II granulocyte population (%)	7.10 (1.2-65.3)	n/a	n/a
	Median (range) PNH Type III granulocyte population (%)	76.0 (4.5-96.4)	11.40 (0.01-99.9)	0.02
15	Median (range) PNH Type II RBC population (%)	3.30 (0.02-71.3)	0.20 (0-76.20)	<0.01
	Median (range) PNH Type III RBC population (%)	16.10 (0.03-86.70)	2.90 (0-92.9)	0.01
20	Median white blood cell (x10 ⁹ /L)	3.80	4.20	0.44
	Median absolute neutrophil count (cells/ μ L)	2.07	2.15	0.70
	Median RBC (x10 ¹² /L)	3.08	3.14	0.80
25	Median hemoglobin (g/dL)	10.6	10.4	0.87
	Median LDH (IU/L)	336	315	0.88
	Median platelets (x10 ⁹ /L)	54	116	0.01
	Platelets < 100 x10 ⁹ /L (%)	68.4 (13/19)	44.0 (62/141)	0.05*
30	*Fisher's exact test.			

[0152] Of the samples from patients in which clinical information was available, 19 (8.8%) patient samples contained distinct Type II granulocyte populations, ranging from 1.2-65.3% of the total granulocyte population, with a median clone size of approximately 7%. In 4 of the 19 patient samples, the Type II granulocyte population represented >50% of the total abnormal population (e.g., PNH Type II and Type III cells). In 10 of the 19 patient samples, a PNH Type II monocyte population was also detected. An evaluation of the ability of various antibodies, specific for individual GPI-linked proteins found on granulocytes, to detect PNH Type II granulocytes indicated that the Type II granulocyte population was detectable in all cases using the detectably-labeled aerolysin reagent, but in decreasing percentages using antibodies specific for CD66b (88%), CD55 (50%), CD24 (47%), and CD16 (0%) (see Table 2). These results indicate that the aerolysin-based conjugate is particularly useful to accurately detect PNH Type II granulocyte populations in patient samples.

Table 2. Detection of Type II granulocytes using aerolysin or other anti-GPI anchored-protein antibodies.

Aerolysin	CD24	CD66b	CD55	CD16
19/19 (100%)	9/19 (47%)	8/9 (88%)	4/8 (50%)	0/9 (0%)

Patient samples containing PNH Type II granulocyte populations had a significantly larger median total combined PNH Type II and PNH Type III granulocyte population than those without Type II granulocytes (87% versus 11%; p = 0.0003), as well as larger median Type II and Type III RBC populations, which reflects an increased ability of the method to detect PNH Type II white blood cell populations in patient samples with overall larger PNH cell populations.

[0153] After comparison with the clinical data it was discovered that patient samples with PNH Type II granulocyte populations also had lower median platelet (plt) counts (54 x 10⁹/L; p<0.01). See Fig. 2. Patient samples with PNH Type II granulocyte populations had similar peripheral white blood cell counts, peripheral red blood cell counts, absolute neutrophil counts, and hemoglobin (Hgb) levels, compared to patient samples without detectable Type II granulocyte populations (Table 1), indicating that differences in platelet counts are likely not due to differences in underlying bone marrow production. In other words, while the disclosure is in no way limited by any particular theory or mechanism of

action, as PNH patients have dysregulated complement control due to the lack of the GPI-linked complement regulatory proteins CD55 and CD59, the decreased platelet counts observed in patients with detectable PNH Type II granulocyte clones may be due to increased terminal complement-mediated platelet consumption or destruction, which may in turn be associated with thrombosis, the leading cause of death among PNH patients.

5

SEQUENCE LISTING

[0154]

10

<110> Alexion Pharmaceuticals, Inc.

<120> REAGENTS AND METHODS FOR DETECTING PNH TYPE II CELLS

15

<130> ALXN-150-WO1

<140> NOT YET ASSIGNED

<141> 2010-11-09

20

<150> 61/280,897

<151> 2009-11-09

<160> 7

25

<170> PatentIn version 3.5

<210> 1

<211> 492

<212> PRT

<213> Aeromonas hydrophila

30

<400> 1

35

40

45

50

55

EP 2 499 494 B1

1 Gln Lys Ile Lys Leu Thr Gly Leu Ser Leu Ile Ile Ser Gly Leu Leu
 5 Met Ala Gln Ala Gln Ala Ala Glu Pro Val Tyr Pro Asp Gln Leu Arg
 10 Leu Phe Ser Leu Gly Gln Gly Val Cys Gly Asp Lys Tyr Arg Pro Val
 15 Asn Arg Glu Glu Ala Gln Ser Val Lys Ser Asn Ile Val Gly Met Met
 20 Gly Gln Trp Gln Ile Ser Gly Leu Ala Asn Gly Trp Val Ile Met Gly
 25 Cys Tyr Pro Thr Asn Pro Val Thr Gly Glu Ile Pro Thr Leu Ser Ala
 30 Leu Asp Ile Pro Asp Gly Asp Glu Val Asp Val Gln Trp Arg Leu Val
 35 His Asp Ser Ala Asn Phe Ile Lys Pro Thr Ser Tyr Leu Ala His Tyr
 40 Leu Gly Tyr Ala Trp Val Gly Gly Asn His Ser Gln Tyr Val Gly Glu
 45
 50
 55

EP 2 499 494 B1

Asp Met Asp Val Thr Arg Asp Gly Asp Gly Trp Val Ile Arg Gly Asn
165 170 175

5 Asn Asp Gly Gly Cys Asp Gly Tyr Arg Cys Gly Asp Lys Thr Ala Ile
180 185 190

10 Lys Val Ser Asn Phe Ala Tyr Asn Leu Asp Pro Asp Ser Phe Lys His
195 200 205

Gly Asp Val Thr Gln Ser Asp Arg Gln Leu Val Lys Thr Val Val Gly
210 215 220

15 Trp Ala Val Asn Asp Ser Asp Thr Pro Gln Ser Gly Tyr Asp Val Thr
225 230 235 240

20 Leu Arg Tyr Asp Thr Ala Thr Asn Trp Ser Lys Thr Asn Thr Tyr Gly
245 250 255

25 Leu Ser Glu Lys Val Thr Thr Lys Asn Lys Phe Lys Trp Pro Leu Val
260 265 270

Gly Glu Thr Glu Leu Ser Ile Glu Ile Ala Ala Asn Gln Ser Trp Ala
275 280 285

30 Ser Gln Asn Gly Gly Ser Thr Thr Thr Ser Leu Ser Gln Ser Val Arg
290 295 300

35 Pro Thr Val Pro Ala Arg Ser Lys Ile Pro Val Lys Ile Glu Leu Tyr
305 310 315 320

Lys Ala Asp Ile Ser Tyr Pro Tyr Glu Phe Lys Ala Asp Val Ser Tyr
325 330 335

40 Asp Leu Thr Leu Ser Gly Phe Leu Arg Trp Gly Gly Asn Ala Trp Tyr
340 345 350

45 Thr His Pro Asp Asn Arg Pro Asn Trp Asn His Thr Phe Val Ile Gly
355 360 365

50 Pro Tyr Lys Asp Lys Ala Ser Ser Ile Arg Tyr Gln Trp Asp Lys Arg
370 375 380

Tyr Ile Pro Gly Glu Val Lys Trp Trp Asp Trp Asn Trp Thr Ile Gln
385 390 395 400

55 Gln Asn Gly Leu Ser Thr Met Gln Asn Asn Leu Ala Arg Val Leu Arg
405 410 415

EP 2 499 494 B1

Pro Val Arg Ala Gly Ile Thr Gly Asp Phe Ser Ala Glu Ser Gln Phe
420 425 430

5 Ala Gly Asn Ile Glu Ile Gly Ala Pro Val Pro Leu Ala Ala Asp Ser
435 440 445

10 His Ser Ser Lys Leu Gln Ser Val Asp Gly Ala Gly Gln Gly Leu Arg
450 455 460

15 Leu Glu Ile Pro Leu Asp Ala Gln Glu Leu Ser Gly Leu Gly Phe Asn
465 470 475 480

Asn Val Ser Leu Ser Val Thr Pro Ala Ala Asn Gln
485 490

<210> 2

20 <211> 470

<212> PRT

<213> Aeromonas hydrophila

25 <400> 2

30

35

40

45

50

55

EP 2 499 494 B1

Ala Glu Pro Val Tyr Pro Asp Gln Leu Arg Leu Phe Ser Leu Gly Gln
 1 5 10 15

5 Gly Val Cys Gly Asp Lys Tyr Arg Pro Val Asn Arg Glu Glu Ala Gln
 20 25 30

10 Ser Val Lys Ser Asn Ile Val Gly Met Met Gly Gln Trp Gln Ile Ser
 35 40 45

15 Gly Leu Ala Asn Gly Trp Val Ile Met Gly Pro Gly Tyr Asn Gly Glu
 50 55 60

20 Ile Lys Pro Gly Thr Ala Ser Asn Thr Trp Cys Tyr Pro Thr Asn Pro
 65 70 75 80

25 Val Thr Gly Glu Ile Pro Thr Leu Ser Ala Leu Asp Ile Pro Asp Gly
 85 90 95

30 Asp Glu Val Asp Val Gln Trp Arg Leu Val His Asp Ser Ala Asn Phe
 100 105 110

35 Ile Lys Pro Thr Ser Tyr Leu Ala His Tyr Leu Gly Tyr Ala Trp Val
 115 120 125

40 Gly Gly Asn His Ser Gln Tyr Val Gly Glu Asp Met Asp Val Thr Arg
 130 135 140

45

50

55

EP 2 499 494 B1

	Asp	Gly	Asp	Gly	Trp	Val	Ile	Arg	Gly	Asn	Asn	Asp	Gly	Gly	Cys	Asp	145	150	155	160
5	Gly	Tyr	Arg	Cys	Gly	Asp	Lys	Thr	Ala	Ile	Lys	Val	Ser	Asn	Phe	Ala	165	170	175	
10	Tyr	Asn	Leu	Asp	Pro	Asp	Ser	Phe	Lys	His	Gly	Asp	Val	Thr	Gln	Ser	180	185	190	
15	Asp	Arg	Gln	Leu	Val	Lys	Thr	Val	Val	Gly	Trp	Ala	Val	Asn	Asp	Ser	195	200	205	
20	Asp	Thr	Pro	Gln	Ser	Gly	Tyr	Asp	Val	Thr	Leu	Arg	Tyr	Asp	Thr	Ala	210	215	220	
25	Thr	Asn	Trp	Ser	Lys	Thr	Asn	Thr	Tyr	Gly	Leu	Ser	Glu	Lys	Val	Thr	225	230	235	240
30	Thr	Lys	Asn	Lys	Phe	Lys	Trp	Pro	Leu	Val	Gly	Glu	Thr	Glu	Leu	Ser	245	250	255	
35	Ile	Glu	Ile	Ala	Ala	Asn	Gln	Ser	Trp	Ala	Ser	Gln	Asn	Gly	Gly	Ser	260	265	270	
40	Thr	Thr	Thr	Ser	Leu	Ser	Gln	Ser	Val	Arg	Pro	Thr	Val	Pro	Ala	Arg	275	280	285	
45	Ser	Lys	Ile	Pro	Val	Lys	Ile	Glu	Leu	Tyr	Lys	Ala	Asp	Ile	Ser	Tyr	290	295	300	
50	Pro	Tyr	Glu	Phe	Lys	Ala	Asp	Val	Ser	Tyr	Asp	Leu	Thr	Leu	Ser	Gly	305	310	315	320
55	Phe	Leu	Arg	Trp	Gly	Gly	Asn	Ala	Trp	Tyr	Thr	His	Pro	Asp	Asn	Arg	325	330	335	
60	Pro	Asn	Trp	Asn	His	Thr	Phe	Val	Ile	Gly	Pro	Tyr	Lys	Asp	Lys	Ala	340	345	350	
65	Ser	Ser	Ile	Arg	Tyr	Gln	Trp	Asp	Lys	Arg	Tyr	Ile	Pro	Gly	Glu	Val	355	360	365	
70	Lys	Trp	Trp	Asp	Trp	Asn	Trp	Thr	Ile	Gln	Gln	Asn	Gly	Leu	Ser	Thr	370	375	380	
75	Met	Gln	Asn	Asn	Leu	Ala	Arg	Val	Leu	Arg	Pro	Val	Arg	Ala	Gly	Ile	385	390	395	400

EP 2 499 494 B1

Thr Gly Asp Phe Ser Ala Glu Ser Gln Phe Ala Gly Asn Ile Glu Ile
 405 410 415
 5
 Gly Ala Pro Val Pro Leu Ala Ala Asp Ser His Ser Ser Lys Leu Gln
 420 425 430
 10
 Ser Val Asp Gly Ala Gly Gln Gly Leu Arg Leu Glu Ile Pro Leu Asp
 435 440 445
 15
 Ala Gln Glu Leu Ser Gly Leu Gly Phe Asn Asn Val Ser Leu Ser Val
 450 455 460
 20
 Thr Pro Ala Ala Asn Gln
 465 470
 <210> 3
 <211> 439
 <212> PRT
 <213> Aeromonas hydrophila
 25
 <400> 3
 Ala Glu Pro Val Tyr Pro Asp Gln Leu Arg Leu Phe Ser Leu Gly Gln
 1 5 10 15
 30
 Gly Val Cys Gly Asp Lys Tyr Arg Pro Val Asn Arg Glu Glu Ala Gln
 20 25 30
 35
 Ser Val Lys Ser Asn Ile Val Gly Met Met Gly Gln Trp Gln Ile Ser
 35 40 45
 40
 Gly Leu Ala Asn Gly Trp Val Ile Met Gly Pro Gly Tyr Asn Gly Glu
 50 55 60
 45
 Ile Lys Pro Gly Thr Ala Ser Asn Thr Trp Cys Tyr Pro Thr Asn Pro
 65 70 75 80
 50
 Val Thr Gly Glu Ile Pro Thr Leu Ser Ala Leu Asp Ile Pro Asp Gly
 85 90 95
 55
 Asp Glu Val Asp Val Gln Trp Arg Leu Val His Asp Ser Ala Asn Phe
 100 105 110

EP 2 499 494 B1

Ile Lys Pro Thr Ser Tyr Leu Ala His Tyr Leu Gly Tyr Ala Trp Val
115 120 125

5 Gly Gly Asn His Ser Gln Tyr Val Gly Glu Asp Met Asp Val Thr Arg
130 135 140

10 Asp Gly Asp Gly Trp Val Ile Arg Gly Asn Asn Asp Gly Gly Cys Asp
145 150 155 160

Gly Tyr Arg Cys Gly Asp Lys Thr Ala Ile Lys Val Ser Asn Phe Ala
165 170 175

15 Tyr Asn Leu Asp Pro Asp Ser Phe Lys His Gly Asp Val Thr Gln Ser
180 185 190

20 Asp Arg Gln Leu Val Lys Thr Val Val Gly Trp Ala Val Asn Asp Ser
195 200 205

25 Asp Thr Pro Gln Ser Gly Tyr Asp Val Thr Leu Arg Tyr Asp Thr Ala
210 215 220

Thr Asn Trp Ser Lys Thr Asn Thr Tyr Gly Leu Ser Glu Lys Val Thr
225 230 235 240

30 Thr Lys Asn Lys Phe Lys Trp Pro Leu Val Gly Glu Thr Glu Leu Ser
245 250 255

Ile Glu Ile Ala Ala Asn Gln Ser Trp Ala Ser Gln Asn Gly Gly Ser
260 265 270

35 Thr Thr Thr Ser Leu Ser Gln Ser Val Arg Pro Thr Val Pro Ala Arg
275 280 285

40 Ser Lys Ile Pro Val Lys Ile Glu Leu Tyr Lys Ala Asp Ile Ser Tyr
290 295 300

45 Pro Tyr Glu Phe Lys Ala Asp Val Ser Tyr Asp Leu Thr Leu Ser Gly
305 310 315 320

Phe Leu Arg Trp Gly Gly Asn Ala Trp Tyr Thr His Pro Asp Asn Arg
325 330 335

50 Pro Asn Trp Asn His Thr Phe Val Ile Gly Pro Tyr Lys Asp Lys Ala
340 345 350

Ser Ser Ile Arg Tyr Gln Trp Asp Lys Arg Tyr Ile Pro Gly Glu Val
355 360 365

55 Lys Trp Trp Asp Trp Asn Trp Thr Ile Gln Gln Asn Gly Leu Ser Thr

EP 2 499 494 B1

	370		375		380												
5	Met	Gln	Asn	Asn	Leu	Ala	Arg	Val	Leu	Arg	Pro	Val	Arg	Ala	Gly	Ile	
	385					390					395					400	
10	Thr	Gly	Asp	Phe	Ser	Ala	Glu	Ser	Gln	Phe	Ala	Gly	Asn	Ile	Glu	Ile	
					405					410					415		
15	Gly	Ala	Pro	Val	Pro	Leu	Ala	Ala	Asp	Ser	His	Ser	Ser	Lys	Leu	Gln	
				420					425					430			
20	Ser	Val	Asp	Gly	Ala	Gly	Gln										
			435														
	<210>	4															
	<211>	128															
	<212>	PRT															
	<213>	Aeromonas hydrophila															
	<400>	4															
25	Leu	Asp	Pro	Asp	Ser	Phe	Lys	His	Gly	Asp	Val	Thr	Gln	Ser	Asp	Arg	
	1				5					10					15		
30	Gln	Leu	Val	Lys	Thr	Val	Val	Gly	Trp	Ala	Val	Asn	Asp	Ser	Asp	Thr	
				20					25					30			
35	Pro	Gln	Ser	Gly	Tyr	Asp	Val	Thr	Leu	Arg	Tyr	Asp	Thr	Ala	Thr	Asn	
			35					40					45				
40	Trp	Ser	Lys	Thr	Asn	Thr	Tyr	Gly	Leu	Ser	Glu	Lys	Val	Thr	Thr	Lys	
	50						55					60					
45	Asn	Lys	Phe	Lys	Trp	Pro	Leu	Val	Gly	Glu	Thr	Glu	Leu	Ser	Ile	Glu	
	65					70					75					80	
50	Ile	Ala	Ala	Asn	Gln	Ser	Trp	Ala	Ser	Gln	Asn	Gly	Gly	Ser	Thr	Thr	
				85						90					95		
55	Thr	Ser	Leu	Ser	Gln	Ser	Val	Arg	Pro	Thr	Val	Pro	Ala	Arg	Ser	Lys	
				100					105					110			
60	Ile	Pro	Val	Lys	Ile	Glu	Leu	Tyr	Lys	Ala	Asp	Ile	Ser	Tyr	Pro	Tyr	
			115					120					125				
65	<210>	5															
	<211>	128															
	<212>	PRT															
	<213>	Aeromonas hydrophila															

EP 2 499 494 B1

<400> 5

5 Leu Asp Pro Asp Ser Phe Lys His Gly Asp Val Thr Gln Ser Asp Arg
1 5 10 15

Gln Leu Val Lys Thr Val Val Gly Trp Ala Val Asn Asp Ser Asp Thr
20 25 30

10 Pro Gln Ser Gly Tyr Asp Val Thr Leu Arg Tyr Asp Thr Ala Thr Asn
35 40 45

15 Trp Ser Lys Thr Asn Thr Tyr Gly Leu Ser Glu Lys Val Thr Thr Lys
50 55 60

20 Asn Lys Phe Lys Trp Pro Leu Val Gly Glu Cys Glu Leu Ser Ile Glu
65 70 75 80

Ile Ala Ala Asn Gln Ser Trp Ala Ser Gln Asn Gly Gly Ser Thr Thr
85 90 95

25 Thr Ser Leu Ser Gln Ser Val Arg Pro Thr Val Pro Ala Arg Ser Lys
100 105 110

30 Ile Pro Val Lys Ile Glu Leu Tyr Lys Cys Asp Ile Ser Tyr Pro Tyr
115 120 125

<210> 6

<211> 492

35 <212> PRT

<213> Aeromonas salmonicida

<400> 6

40

45

50

55

EP 2 499 494 B1

Met Lys Lys Leu Lys Ile Thr Gly Leu Ser Leu Ile Ile Ser Gly Leu
 1 5 10 15
 5
 Leu Met Ala Gln Ala Gln Ala Ala Glu Pro Val Tyr Pro Asp Gln Leu
 20 25 30
 10
 Arg Leu Phe Ser Leu Gly Gln Glu Val Cys Gly Asp Lys Tyr Arg Pro
 35 40 45
 15
 Val Asn Arg Glu Glu Ala Gln Ser Val Lys Ser Asn Ile Val Gly Met
 50 55 60
 20
 Met Gly Gln Trp Gln Ile Ser Gly Leu Ala Asn Gly Trp Val Ile Met
 65 70 75 80
 25
 Gly Pro Gly Tyr Asn Gly Glu Ile Lys Pro Gly Ser Ala Ser Ser Thr
 85 90 95
 30
 35
 40
 45
 50
 55
 Trp Cys Tyr Pro Thr Asn Pro Ala Thr Gly Glu Ile Pro Thr Leu Ser
 100 105 110

EP 2 499 494 B1

Ala Leu Asp Ile Pro Asp Gly Asp Glu Val Asp Val Gln Trp Arg Leu
115 120 125

5 Val His Asp Ser Ala Asn Phe Ile Lys Pro Thr Ser Tyr Leu Ala His
130 135 140

10 Tyr Leu Gly Tyr Ala Trp Val Gly Gly Asn His Ser Gln Tyr Val Gly
145 150 155 160

15 Glu Asp Met Asp Val Thr Arg Asp Gly Asp Gly Trp Val Ile Arg Gly
165 170 175

20 Asn Asn Asp Gly Gly Cys Asp Gly Tyr Arg Cys Gly Asp Lys Thr Ser
180 185 190

Ile Lys Val Ser Asn Phe Ala Tyr Asn Leu Asp Pro Asp Ser Phe Lys
195 200 205

25 His Gly Asp Val Thr Gln Ser Asp Arg Gln Leu Val Lys Thr Val Val
210 215 220

Gly Trp Ala Ile Asn Asp Ser Asp Thr Pro Gln Ser Gly Tyr Asp Val
225 230 235 240

30 Thr Leu Arg Tyr Asp Thr Ala Thr Asn Trp Ser Lys Thr Asn Thr Tyr
245 250 255

35 Gly Leu Ser Glu Lys Val Thr Thr Lys Asn Lys Phe Lys Trp Pro Leu
260 265 270

40 Val Gly Glu Thr Glu Leu Ser Ile Glu Ile Ala Ala Asn Gln Ser Trp
275 280 285

Ala Ser Gln Asn Gly Gly Ser Thr Thr Thr Ser Leu Ser Gln Ser Val
290 295 300

45 Arg Pro Thr Val Pro Ala His Ser Lys Ile Pro Val Lys Ile Glu Leu
305 310 315 320

50 Tyr Lys Ala Asp Ile Ser Tyr Pro Tyr Glu Phe Lys Ala Asp Val Ser
325 330 335

Tyr Asp Leu Thr Leu Ser Gly Phe Leu Arg Trp Gly Gly Asn Ala Trp
340 345 350

55 Tyr Thr His Pro Asp Asn Arg Pro Asn Trp Asn His Thr Phe Val Ile
355 360 365

EP 2 499 494 B1

Gly Pro Tyr Lys Asp Lys Ala Ser Ser Ile Arg Tyr Gln Trp Asp Lys
 370 375 380

5

Arg Tyr Ile Pro Gly Glu Val Lys Trp Ser Asp Trp Asn Trp Thr Ile
 385 390 395 400

10

Gln Gln Asn Gly Leu Ser Thr Met Gln Asn Asn Leu Ala Arg Val Leu
 405 410 415

15

Arg Pro Val Arg Ala Gly Ile Thr Gly Asp Phe Ser Ala Glu Ser Gln
 420 425 430

20

Phe Ala Gly Asn Ile Glu Ile Gly Ala Pro Val Pro Val Ala Ala Ala
 435 440 445

25

Ser Gln Ser Ser Arg Ala Arg Asn Leu Ser Ala Gly Gln Gly Leu Arg
 450 455 460

Leu Glu Ile Pro Leu Asp Ala Gln Glu Leu Ser Gly Leu Gly Phe Asn
 465 470 475 480

30

Asn Val Ser Leu Ser Val Thr Pro Ala Ala Asn Gln
 485 490

35

<210> 7
 <211> 469
 <212> PRT
 <213> Aeromonas salmonicida

40

Ala Glu Pro Val Tyr Pro Asp Gln Leu Arg Leu Phe Ser Leu Gly Gln
 1 5 10 15

45

Glu Val Cys Gly Asp Lys Tyr Arg Pro Val Asn Arg Glu Glu Ala Gln
 20 25 30

50

Ser Val Lys Ser Asn Ile Val Gly Met Met Gly Gln Trp Gln Ile Ser
 35 40 45

55

EP 2 499 494 B1

Gly Leu Ala Asn Gly Trp Val Ile Met Gly Pro Gly Tyr Asn Gly Glu
 50 55 60

5 Ile Lys Pro Gly Ser Ala Ser Ser Thr Trp Cys Tyr Pro Thr Asn Pro
 65 70 75 80

10 Ala Thr Gly Glu Ile Pro Thr Leu Ser Ala Leu Asp Ile Pro Asp Gly
 85 90 95

Asp Glu Val Asp Val Gln Trp Arg Leu Val His Asp Ser Ala Asn Phe
 100 105 110

15 Ile Lys Pro Thr Ser Tyr Leu Ala His Tyr Leu Gly Tyr Ala Trp Val
 115 120 125

20 Gly Gly Asn His Ser Gln Tyr Val Gly Glu Asp Met Asp Val Thr Arg
 130 135 140

Asp Gly Asp Gly Trp Val Ile Arg Gly Asn Asn Asp Gly Gly Cys Asp
 145 150 155 160

25 Gly Tyr Arg Cys Gly Asp Lys Thr Ser Ile Lys Val Ser Asn Phe Ala
 165 170 175

30 Tyr Asn Leu Asp Pro Asp Ser Phe Lys His Gly Asp Val Thr Gln Ser
 180 185 190

Asp Arg Gln Leu Val Lys Thr Val Val Gly Trp Ala Ile Asn Asp Ser
 195 200 205

Asp Thr Pro Gln Ser Gly Tyr Asp Val Thr Leu Arg Tyr Asp Thr Ala
 210 215 220

40 Thr Asn Trp Ser Lys Thr Asn Thr Tyr Gly Leu Ser Glu Lys Val Thr
 225 230 235 240

Thr Lys Asn Lys Phe Lys Trp Pro Leu Val Gly Glu Thr Glu Leu Ser
 245 250 255

Ile Glu Ile Ala Ala Asn Gln Ser Trp Ala Ser Gln Asn Gly Gly Ser
 260 265 270

50 Thr Thr Thr Ser Leu Ser Gln Ser Val Arg Pro Thr Val Pro Ala His
 275 280 285

55 Ser Lys Ile Pro Val Lys Ile Glu Leu Tyr Lys Ala Asp Ile Ser Tyr
 290 295 300

EP 2 499 494 B1

Pro Tyr Glu Phe Lys Ala Asp Val Ser Tyr Asp Leu Thr Leu Ser Gly
 305 310 315 320
 5
 Phe Leu Arg Trp Gly Gly Asn Ala Trp Tyr Thr His Pro Asp Asn Arg
 325 330 335
 10
 Pro Asn Trp Asn His Thr Phe Val Ile Gly Pro Tyr Lys Asp Lys Ala
 340 345 350
 15
 Ser Ser Ile Arg Tyr Gln Trp Asp Lys Arg Tyr Ile Pro Gly Glu Val
 355 360 365
 20
 Lys Trp Ser Asp Trp Asn Trp Thr Ile Gln Gln Asn Gly Leu Ser Thr
 370 375 380
 25
 Met Gln Asn Asn Leu Ala Arg Val Leu Arg Pro Val Arg Ala Gly Ile
 385 390 395 400
 30
 Thr Gly Asp Phe Ser Ala Glu Ser Gln Phe Ala Gly Asn Ile Glu Ile
 405 410 415
 35
 Gly Ala Pro Val Pro Val Ala Ala Ala Ser Gln Ser Ser Arg Ala Arg
 420 425 430
 40
 Asn Leu Ser Ala Gly Gln Gly Leu Arg Leu Glu Ile Pro Leu Asp Ala
 435 440 445
 45
 Gln Glu Leu Ser Gly Leu Gly Phe Asn Asn Val Ser Leu Ser Val Thr
 450 455 460
 50
 Pro Ala Ala Asn Gln
 465

25658410_1

1

25658410_1

25658410_1

Claims

1. A method for predicting whether a patient afflicted with paroxysmal nocturnal hemoglobinuria (PNH) is at an increased risk for developing thrombosis, the method comprising:

determining the percentage of PNH Type II granulocytes of the total granulocytes in a whole blood sample from a patient; and
 predicting whether the patient is at an increased risk for developing thrombosis,

wherein the patient is at an increased risk for developing thrombosis if the percentage of PNH Type II granulocytes is greater than or equal to 1.2%.

- 5 2. The method of claim 1, wherein a PNH Type II granulocyte population that is between 1.2% to 65.3%, inclusive of 1.2% and 65.3%, indicates that the patient is at an increased risk for thrombosis.
3. The method of claim 1 or 2, wherein a PNH Type II granulocyte population that is greater than or equal to a) 5%, b) 10%, c) 20% or d) 50% indicates that the-patient is at an increased risk for thrombosis.
- 10 4. The method of any one of claims 1 to 3, further comprising monitoring the patient for the development of at least one symptom of thrombosis if the patient is at an increased risk of developing thrombosis.
5. The method of any one of claims 1 to 4, further comprising selecting an anti-thrombotic therapy for the patient if the patient is at an increased risk of developing thrombosis.
- 15 6. The method of claim 5, wherein the anti-thrombotic therapy is an anticoagulant or thrombolytic agent.
7. The method of claim 6, wherein the anticoagulant is coumadin, heparin, or derivatives thereof.
- 20 8. The method of claim 6, wherein the thrombolytic agent is a tissue plasminogen activator, streptokinase, or a urokinase-type plasminogen activator.
9. A method for selecting a therapy for a patient afflicted with paroxysmal nocturnal hemoglobinuria (PNH), the method comprising: (a) determining the percentage of PNH type II granulocytes of the total granulocytes in a whole blood sample of the patient according to the method of claim 1 and (b) selecting one or both of an anti-thrombotic therapy and an anti-thrombocytopenic therapy for a patient determined to have a percentage of PNH Type II granulocytes of greater than or equal to 1.2%.
- 25 10. An anticoagulant or thrombolytic agent for use in treating a patient afflicted with paroxysmal nocturnal hemoglobinuria (PNH), wherein the patient has a PNH Type II granulocyte population of greater than 1.2%.
- 30 11. The method of claim 9, wherein the anti-thrombocytopenic therapy is a platelet transfusion.
12. The method of any one of claims 1 to 9 or 11 or the anticoagulant or thrombolytic agent for use according to claim 10, wherein a non-lytic variant form of aerolysin protein is used to determine the percentage of PNH Type II granulocytes.
- 35 13. The method of: (a) any one of claims 1 to 8, wherein the step of determining the percentage of PNH Type II granulocytes comprises, or (b) claim 9, wherein the percentage of PNH Type II granulocytes is determined by:
 - 40 contacting white blood cells with a reagent that binds to: (i) GPI or (ii) a GPI-anchored protein, wherein the white blood cells are obtained from the whole blood sample;
 - determining the amount of binding of the reagent;
 - 45 comparing the amount of binding of the reagent among the granulocytes, wherein granulocytes that exhibit an intermediate amount of binding are classified as PNH Type II granulocytes; and
 - determining the percentage of PNH Type II granulocytes.
14. The method of claim 13, further comprising determining the percentage of PNH Type III granulocytes.
- 50 15. The method of claim 13 or 14, wherein the distinguishing comprises flow cytometry.
16. The method of any one of claims 13 to 15, wherein the reagent binds to a human GPI moiety.
17. The method of claim 16, wherein the reagent comprises an aerolysin protein.
- 55 18. The method of claim 16 or 17, wherein the reagent comprises a variant form of aerolysin protein that is non-lytic or is non-lytic as compared to the wild-type form of the protein.

19. The method of any one of claims 16 to 18, wherein the reagent comprises the amino acid sequence depicted in SEQ ID NO:2 or 7 wherein the threonine at position 253 is substituted with a cysteine and the alanine at position 300 is substituted for a cysteine.

5 20. The method of any one of claims 13 to 16 wherein the reagent is an antibody or an antigen-binding fragment thereof.

21. The method of any one of claims 13 to 16 or 20, wherein the reagent binds to a GPI-anchored protein.

10 22. The method of claim 21, wherein the GPI-anchored protein is selected from the group consisting of alkaline phosphatase, 5' nucleotidase acetylcholinesterase, dipeptidase, LFA-3, NCAM, PH-20, CD55, CD59, Thy-1, Qa-2, CD14, CD33, CD16 (the Fc γ receptor III), carcinoembryonic antigen (CEA), CD24, CD66b, CD87, CD48, and CD52.

Patentansprüche

15 1. Verfahren zur Vorhersage, ob ein Patient, der von paroxysmaler nächtlicher Hämoglobinurie (PNH) betroffen ist, ein erhöhtes Risiko für die Entwicklung einer Thrombose hat, wobei das Verfahren Folgendes umfasst:

20 Bestimmen des Prozentanteils an PNH-Typ-II-Granulozyten an der Gesamtzahl von Granulozyten in einer Vollblutprobe von einem Patienten; und
Vorhersagen, ob der Patient ein erhöhtes Risiko für die Entwicklung einer Thrombose hat, wobei der Patient ein erhöhtes Risiko für die Entwicklung einer Thrombose hat, wenn der Prozentanteil an PNH-Typ-II-Granulozyten mindestens 1,2 % beträgt.

25 2. Verfahren nach Anspruch 1, wobei eine Population an PNH-Typ-II-Granulozyten, die zwischen 1,2 % und 65,3 % beträgt, einschließlich 1,2 % und 65,3 %, anzeigt, dass der Patient ein erhöhtes Thromboserisiko hat.

30 3. Verfahren nach Anspruch 1 oder 2, wobei eine Population an PNH-Typ-II-Granulozyten, die mindestens a) 5 %, b) 10 %, c) 20 % oder d) 50 % beträgt, anzeigt, dass der Patient ein erhöhtes Thromboserisiko hat.

4. Verfahren nach einem beliebigen der Ansprüche 1 bis 3, welches weiterhin das Überwachen des Patienten hinsichtlich der Entwicklung mindestens eines Thrombosesymptoms umfasst, wenn der Patient ein erhöhtes Risiko für die Entwicklung einer Thrombose hat.

35 5. Verfahren nach einem beliebigen der Ansprüche 1 bis 4, welches weiterhin die Auswahl einer thrombosebekämpfenden Therapie für den Patienten umfasst, wenn der Patient ein erhöhtes Risiko für die Entwicklung einer Thrombose hat.

40 6. Verfahren nach Anspruch 5, wobei es sich bei der thrombosebekämpfenden Therapie um ein gerinnungshemmendes oder thrombolytisches Mittel handelt.

7. Verfahren nach Anspruch 6, wobei es sich bei dem gerinnungshemmenden Mittel um Coumadin, Heparin oder deren Derivate handelt.

45 8. Verfahren nach Anspruch 6, wobei es sich bei dem thrombolytischen Mittel um einen gewebespezifischen Plasminogenaktivator, um Streptokinase oder um einen Plasminogenaktivator vom Urokinase-Typ handelt.

50 9. Verfahren zur Auswahl einer Therapie für einen Patienten, der von paroxysmaler nächtlicher Hämoglobinurie (PNH) betroffen ist, wobei das Verfahren Folgendes umfasst: (a) Bestimmen des Prozentanteils an PNH-Typ-II-Granulozyten an der Gesamtzahl von Granulozyten in einer Vollblutprobe des Patienten nach dem Verfahren des Anspruchs 1 und (b) Auswahl einer thrombosebekämpfenden Therapie und/oder einer thrombozytopeniebekämpfenden Therapie für einen Patienten, bei welchem festgestellt wurde, dass er einen Prozentanteil an PNH-Typ-II-Granulozyten von mindestens 1,2 % hat.

55 10. Gerinnungshemmendes oder thrombolytisches Mittel zur Verwendung bei der Behandlung eines Patienten, der von paroxysmaler nächtlicher Hämoglobinurie (PNH) betroffen ist, wobei der Patient eine Population an PNH-Typ-II-Granulozyten von mehr als 1,2 % aufweist.

EP 2 499 494 B1

11. Verfahren nach Anspruch 9, wobei es sich bei der thrombozytopeniebekämpfenden Therapie um eine Transfusion von Blutplättchen handelt.
- 5 12. Verfahren nach einem beliebigen der Ansprüche 1 bis 9 oder 11, oder gerinnungshemmendes oder thrombolytisches Mittel zur Verwendung nach Anspruch 10, wobei eine nicht-lytische Variante von Aerolysinprotein dazu verwendet wird, den Prozentanteil an PNH-Typ-II-Granulozyten zu bestimmen.
- 10 13. Verfahren nach: (a) einem beliebigen der Ansprüche 1 bis 8, wobei der Schritt des Bestimmens des Prozentanteils an PNH-Typ-II-Granulozyten Folgendes umfasst, oder b) Anspruch 9, wobei der Prozentanteil an PNH-Typ-II-Granulozyten folgendermaßen bestimmt wird:
- 15 Inkontaktbringen weißer Blutkörperchen mit einem Reagenz, das an Folgendes bindet: (i) GPI oder (ii) ein fest an GPI gebundenes Protein, wobei die weißen Blutkörperchen aus der Vollblutprobe gewonnen werden; Bestimmen des Ausmaßes der Bindung des Reagenzes; Vergleichen des Ausmaßes der Bindung des Reagenzes in Gegenwart der Granulozyten, wobei Granulozyten, die ein mittelgroßes Ausmaß der Bindung zeigen, als PNH-Typ-II-Granulozyten eingestuft werden; und Bestimmen des Prozentanteils an PNH-Typ-II-Granulozyten.
- 20 14. Verfahren nach Anspruch 13, welches weiterhin das Bestimmen des Prozentanteils an PNH-Typ-III-Granulozyten umfasst.
15. Verfahren nach Anspruch 13 oder 14, wobei der Unterscheidungsvorgang Durchflusszytometrie umfasst.
- 25 16. Verfahren nach einem beliebigen der Ansprüche 13 bis 15, wobei das Reagenz an einen GPI-Baustein des Menschen bindet.
17. Verfahren nach Anspruch 16, wobei das Reagenz ein Aerolysinprotein umfasst.
- 30 18. Verfahren nach Anspruch 16 oder 17, wobei das Reagenz ein Variante von Aerolysinprotein umfasst, die nicht-lytisch ist oder die im Vergleich mit der Wildtypform des Proteins nicht-lytisch ist.
- 35 19. Verfahren nach einem beliebigen der Ansprüche 16 bis 18, wobei das Reagenz die Aminosäuresequenz umfasst, welche in der SEQ ID Nr. 2 oder 7 dargestellt ist, wobei das Threonin an Position 253 durch ein Cystein ersetzt ist und das Alanin an Position 300 durch ein Cystein ersetzt ist.
- 40 20. Verfahren nach einem beliebigen der Ansprüche 13 bis 16, wobei es sich bei dem Reagenz um einen Antikörper oder ein antigenbindendes Fragment eines solchen handelt.
- 45 21. Verfahren nach einem beliebigen der Ansprüche 13 bis 16 oder 20, wobei das Reagenz an ein fest an GPI gebundenes Protein bindet.
22. Verfahren nach Anspruch 21, wobei das fest an GPI gebundene Protein aus der Gruppe ausgewählt ist, die aus alkalischer Phosphatase, 5'-Nukleotidase-Acetylcholinesterase, Dipeptidase, LFA-3, NCAM, PH-20, CD55, CD59, Thy-1, Qa-2, CD14, CD33, CD16 (dem Fc γ -Rezeptor III), karzinoembryonischem Antigen (CEA), CD24, CD66b, CD87, CD48 und CD52 besteht.

Revendications

- 50 1. Procédé pour prédire si un patient atteint d'hémoglobinurie paroxystique nocturne (HPN) a un risque accru de développer une thrombose, le procédé comprenant :
- 55 la détermination du pourcentage de granulocytes de HPN de type II sur les granulocytes totaux dans un échantillon de sang total issu d'un patient ; et
la prédiction pour savoir si le patient a un risque accru de développer une thrombose, dans lequel le patient a un risque accru de développer une thrombose si le pourcentage de granulocytes de HPN de type II est supérieur ou égal à 1,2 %.

EP 2 499 494 B1

2. Procédé selon la revendication 1, dans lequel une population de granulocytes de HPN de type II qui est entre 1,2 % inclus et 65,3 % inclus, indique que le patient a un risque accru de thrombose.
- 5 3. Procédé selon la revendication 1 ou 2, dans lequel une population de granulocytes de HPN de type II qui est supérieure ou égale à a) 5 %, b) 10 %, c) 20 % ou d) 50 % indique que le patient a un risque accru de thrombose.
- 10 4. Procédé selon l'une quelconque des revendications 1 à 3, comprenant en outre la surveillance du patient concernant le développement d'au moins un symptôme de thrombose si le patient a un risque accru de développer une thrombose.
- 15 5. Procédé selon l'une quelconque des revendications 1 à 4, comprenant en outre la sélection d'une thérapie antithrombotique pour le patient si le patient a un risque accru de développer une thrombose.
- 20 6. Procédé selon la revendication 5, dans lequel la thérapie antithrombotique est un anticoagulant ou un agent thrombolytique.
- 25 7. Procédé selon la revendication 6, dans lequel l'anticoagulant est la coumadine, l'héparine ou leurs dérivés.
- 30 8. Procédé selon la revendication 6, dans lequel l'agent thrombolytique est un activateur tissulaire du plasminogène, la streptokinase ou un activateur de plasminogène de type urokinase.
- 35 9. Procédé pour sélectionner une thérapie pour un patient atteint d'hémoglobinurie paroxystique nocturne (HPN), le procédé comprenant : (a) la détermination du pourcentage de granulocytes de HPN de type II sur les granulocytes totaux dans un échantillon de sang total du patient selon le procédé de la revendication 1 et (b) la sélection de l'une d'une thérapie antithrombotique ou d'une thérapie antithrombocytopénique ou des deux pour un patient déterminé comme ayant un pourcentage de granulocytes de HPN de type II supérieur ou égal à 1,2 %.
- 40 10. Agent anticoagulant ou thrombolytique pour une utilisation dans le traitement d'un patient atteint d'hémoglobinurie paroxystique nocturne (HPN), dans lequel le patient a une population de granulocytes de HPN de type II supérieure à 1,2 %.
- 45 11. Procédé selon la revendication 9, dans lequel la thérapie antithrombocytopénique est une transfusion de plaquettes.
- 50 12. Procédé selon l'une quelconque des revendications 1 à 9 ou 11, ou agent anticoagulant ou thrombolytique pour une utilisation selon la revendication 10, dans lequel une forme de variant non lytique de protéine aérolysine est utilisée pour déterminer le pourcentage de granulocytes de HPN de type II.
- 55 13. Procédé selon : (a) l'une quelconque des revendications 1 à 8, dans lequel l'étape de détermination du pourcentage de granulocytes de HPN de type II comprend, ou (b) selon la revendication 9, dans lequel le pourcentage de granulocytes de HPN de type II est déterminé par :
 - la mise en contact de globules blancs avec un réactif qui se lie à : (i) GPI ou (ii) une protéine ancrée à GPI, dans lequel les globules blancs sont obtenus à partir de l'échantillon de sang total ;
 - la détermination de la quantité de liaison du réactif ; la comparaison de la quantité de liaison du réactif parmi les granulocytes, dans lequel des granulocytes qui présentent une quantité intermédiaire de liaison sont classifiés en tant que granulocytes de HPN de type II ; et
 - la détermination du pourcentage de granulocytes de HPN de type II.
14. Procédé selon la revendication 13, comprenant en outre la détermination du pourcentage de granulocytes de HPN de type III.
15. Procédé selon la revendication 13 ou 14, dans lequel la distinction comprend une cytométrie en flux.
16. Procédé selon l'une quelconque des revendications 13 à 15, dans lequel le réactif se lie à un fragment de GPI humain.
17. Procédé selon la revendication 16, dans lequel le réactif comprend une protéine aérolysine.
18. Procédé selon la revendication 16 ou 17, dans lequel le réactif comprend une forme de variant de protéine aérolysine

EP 2 499 494 B1

qui est non lytique ou est non lytique comparée à la forme de type sauvage de la protéine.

- 5
19. Procédé selon l'une quelconque des revendications 16 à 18, dans lequel le réactif comprend la séquence d'acides aminés représentée dans SEQ. ID. n° 2 ou 7, dans lequel la thréonine en position 253 est substituée par une cystéine et l'alanine en position 300 est substituée par une cystéine.
- 10
20. Procédé selon l'une quelconque des revendications 13 à 16, dans lequel le réactif est un anticorps ou un fragment de liaison à l'antigène de celui-ci.
- 15
21. Procédé selon l'une quelconque des revendications 13 à 16 ou 20, dans lequel le réactif se lie à une protéine ancrée à GPI.
22. Procédé selon la revendication 21, dans lequel la protéine ancrée à GPI est choisie dans le groupe constitué de phosphatase alcaline, 5' nucleotidase acétylcholinestérase, dipeptidase, LFA-3, NCAM, PH-20, CD55, CD59, Thy-1, Qa-2, CD14, CD33, CD16 (le récepteur Fc γ III), antigène carcinoembryonnaire (CEA), CD24, CD66b, CD87, CD48 et CD52.

20

25

30


35

40

45

50

55



Log intensity of signal from a anti-CD24 antibody-phycoerythrin (PE) conjugate bound to the cells

Log intensity of signal from a non-lytic aerolysin-AlexaFluor® 488 conjugate bound to the cells

Fig. 1

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 61280897 A [0001]
- US 6593095 B, Buckley and Brodsky [0005] [0122]
- US 612006555 A [0069]
- US 4376110 A [0082]
- WO 9708320 A [0083]
- US 5427908 A [0083]
- US 5508717 A [0083]
- US 5403484 A [0083]
- US 5223409 A [0083]
- WO 8806630 A [0083]
- WO 9215679 A [0083]
- US 5780279 A [0083]
- US 5571698 A [0083]
- US 6040136 A [0083]
- US 4816567 A [0090]
- US 6794132 B [0093]
- US 66802094634666 A [0093]
- US 5939598 A [0095]
- US 6673986 B [0095]
- US 6114598 A [0095]
- US 6075181 A [0095]
- US 6162963 A [0095]
- US 6150584 A [0095]
- US 6713610 B [0095]
- US 6657103 B [0095]
- US 20030229905 A1 [0095]
- US 20040010810 A1 [0095]
- US 20040093622 A1 [0095]
- US 20060040363 A1 [0095]
- US 20050054055 A1 [0095]
- US 20050076395 A1 [0095]
- US 20050287630 A1 [0095]
- WO 9402602 A [0095]
- WO 9634096 A [0095]
- WO 9824893 A [0095]
- EP 0463151 B1 [0095]
- US 5545807 A [0096]
- US 5545806 A [0096]
- US 5625825 A [0096]
- US 5625126 A [0096]
- US 5633425 A [0096]
- US 5661016 A [0096]
- US 5770429 A [0096]
- US 5789650 A [0096]
- US 5814318 A [0096]
- US 5591669 A [0096]
- US 5612205 A [0096]
- US 5721367 A [0096]
- US 5789215 A [0096]
- US 5643763 A [0096]
- US 5569825 A [0096]
- US 5877397 A [0096]
- US 6300129 B [0096]
- US 5874299 A [0096]
- US 6255458 B [0096]
- US 7041871 B [0096]
- EP 0546073 B1 [0096]
- WO 9203918 A [0096]
- WO 9222645 A [0096]
- WO 9222647 A [0096]
- WO 9222670 A [0096]
- WO 9312227 A [0096]
- WO 9400569 A [0096]
- WO 9425585 A [0096]
- WO 9614436 A [0096]
- WO 9713852 A [0096]
- WO 9824884 A [0096]
- WO 04108158 A [0097]
- WO 0034317 A [0097]
- WO 02069232 A [0097]
- WO 9627011 A [0109]
- US 4676980 A [0109]
- US 6001329 A [0113]
- US 20030049683 A [0135]
- WO 61280897 A [0154]

Non-patent literature cited in the description

- ALXN150WO1.txt, 05 November 2010 [0002]
- ROSSE ; NISHIMURA. *IntJHematol*, 2003, vol. 77 (2), 121-124 [0004]
- BRODSKY. *Blood Rev*, 2008, vol. 22 (2), 65-74 [0004]
- MIYATA et al. *Science*, 1993, vol. 259, 1318-1320 [0004]
- BESSLER et al. *EMBO J*, 1994, vol. 13, 110-117 [0004]
- ROSSE. *Medicine*, 1997, vol. 76, 63-93 [0004]
- NICHOLSON-WELLER et al. *Proc Natl Acad Sci USA*, 1983, vol. 80, 5066-5070 [0004]
- YAMASHINA et al. *N Engl J Med*, 1990, vol. 323, 1184-1189 [0004]

- **SUTHERLAND et al.** *Am J Clin Pathol*, 2009, vol. 132, 564-572 [0005]
- **BRODSKY et al.** *Am J Clin Pathol*, 2000, vol. 114, 459-466 [0005] [0063] [0127]
- **PAULICK ; BERTOZZI.** *Biochemistry*, 2008, vol. 47 (27), 6991-7000 [0050]
- **HOWARD ; BUCKLEY.** *J Bacteriol*, 1985, vol. 163, 336-340 [0051]
- **HONG et al.** *EMBO J*, 2002, vol. 21 (19), 5047-5056 [0065]
- **HOWARD ; BUCKLEY.** *Biochemistry*, 1982, vol. 21 (7), 1662-1667 [0066]
- **AVIGAD ; BEMHEIMER.** *Infection and Immunity*, 1976, vol. 13 (5), 1378-1381 [0066]
- **GARLAND ; BUCKLEY.** *Infection and Immunity*, 1988, vol. 56 (5), 1249-1253 [0066]
- **BERNHEIMER ; AVIGARD.** *Infection and Immunity*, 1974, vol. 9, 1016-1021 [0066]
- **SAMBROOK et al.** *Molecular Cloning: A Laboratory Manual.* Cold Spring Harbor Laboratory Press, 1989 [0067]
- **AUSUBEL et al.** *Current Protocols in Molecular Biology.* Greene Publishing Associates, 1992 [0067]
- **HOWARD et al.** *J Bacteriol*, 1987, vol. 169 (6), 2869-2871 [0067]
- **BUCKLEY.** *Biochem. Cell Biol.*, 1990, vol. 68, 221-224 [0067]
- **WONG et al.** *J Bacteriol.*, 1989, vol. 171, 2523-2527 [0067]
- **NAIK et al.** *Infection and Immunity*, 2006, vol. 74 (2), 1412 [0070]
- **TODOROVSKA et al.** *J Immunol Methods*, 2001, vol. 248 (1), 47-66 [0071]
- **HUDSON ; KORTT.** *J Immunol Methods*, 1999, vol. 231 (1), 177-189 [0071]
- **POLJAK.** *Structure*, 1994, vol. 2 (12), 1121-1123 [0071]
- **RONDON ; MARASCO.** *Annual Review of Microbiology*, 1997, vol. 51, 257-283 [0071]
- **RICHARDS et al.** *Cytometry B Clin Cytom*, 2008, vol. 76B (1), 47-55 [0072]
- **RICHARDS ; BARNETT.** *Clin Lab Med*, 2007, vol. 27 (3), 577-590 [0072]
- **LUZZATTO et al.** *Int J Hematol*, 2006, vol. 84 (2), 104-112 [0072]
- **THOMASON et al.** *Am J Clin Pathol*, 2004, vol. 122 (1), 128-134 [0072]
- **KOHLER ; MILSTEIN.** *Nature*, 1975, vol. 256, 495-497 [0082]
- **HARLOW ; LANE.** *Antibodies: a Laboratory Manual.* Cold Spring Harbor, 1988 [0082]
- **SMITH.** *Science*, 1985, vol. 225, 1315-1317 [0083]
- **PARMLEY ; SMITH.** *Gene*, 1988, vol. 73, 305-318 [0083]
- **DE LA CRUZ et al.** *Journal of Biological Chemistry*, 1988, vol. 263, 4318-4322 [0083]
- **DAVIS et al.** *Cancer Metastasis Rev.*, 1999, vol. 18 (4), 421-5 [0083]
- **TAYLOR et al.** *Nucleic Acids Research*, 1992, vol. 20, 6287-6295 [0083]
- **TOMIZUKA et al.** *Proc. Natl. Acad. Sci. USA*, 2000, vol. 97 (2), 722-727 [0083]
- **JONES et al.** *Nature*, 1986, vol. 321, 522-525 [0091]
- **RIECHMANN et al.** *Nature*, 1988, vol. 332, 323-327 [0091]
- **VERHOEYEN et al.** *Science*, 1988, vol. 239, 1534-1536 [0091]
- **STAELENS et al.** *Mol Immunol*, 2006, vol. 43, 1243-1257 [0091]
- **JAKOBOVITS et al.** *Proc. Natl. Acad. Sci. USA*, 1993, vol. 90, 2551 [0092]
- **JAKOBOVITS et al.** *Nature*, 1993, vol. 362, 255-258 [0092]
- **BRUGEMANN et al.** *Year in Immunol.*, 1993, vol. 7, 33 [0092]
- **DUCHOSAL et al.** *Nature*, 1992, vol. 355, 258 [0092]
- **HOOGENBOOM et al.** *J. Mol. Biol.*, 1991, vol. 227, 381 [0093]
- **MARKS et al.** *J. Mol. Biol.*, 1991, vol. 222, 581-597 [0093]
- **VAUGHAN et al.** *Nature Biotech*, 1996, vol. 14, 309 [0093]
- **OSTBERG et al.** *Hybridoma*, 1983, vol. 2, 361-367 [0093]
- **MENDEZ et al.** *Nature Genetics*, 1998, vol. 15, 146-156 [0094]
- **GREEN ; JAKOBOVITS.** *J. Exp. Med.*, 1998, vol. 188, 483-495 [0094]
- **TAYLOR et al.** *Nucleic Acids Res.*, 1992, vol. 20, 6287 [0096]
- **CHEN et al.** *Int. Immunol.*, 1993, vol. 5, 647 [0096]
- **TUAILLON et al.** *Proc. Natl. Acad. Sci. USA*, 1993, vol. 90, 3720-4 [0096]
- **CHOI et al.** *Nature Genetics*, 1993, vol. 4, 117 [0096]
- **LONBERG et al.** *Nature*, 1994, vol. 368, 856-859 [0096]
- **TAYLOR et al.** *International Immunology*, 1994, vol. 6, 579-591 [0096]
- **TUAILLON et al.** *J. Immunol.*, 1995, vol. 154, 6453-65 [0096]
- **FISHWILD et al.** *Nature Biotechnology*, 1996, vol. 14, 845 [0096]
- **TUAILLON et al.** *Eur. J. Immunol.*, 2000, vol. 10, 2998-3005 [0096]
- **MULLIGAN ; BERG.** *Proc. Natl. Acad. Sci. USA*, 1981, vol. 78, 2072 [0105]
- **SOUTHERN ; BERG.** *Mol. Appl. Genet.*, 1982, vol. 1, 327 [0105]
- **WIGLER et al.** *Cell*, 1979, vol. 16, 77 [0105]
- **SARVER et al.** *Proc. Natl. Acad. Sci. USA*, 1982, vol. 79, 7147 [0105]
- **DEANS et al.** *Proc. Natl. Acad. Sci. USA*, 1984, vol. 81, 1292 [0105]
- **LUSKY ; BOTCHAN.** *Nature*, 1981, vol. 293, 79 [0105]

- **OKAYAMA ; BERG.** *Mol. Cell Biol.*, 1983, vol. 3, 280 [0106]
- **CEPKO et al.** *Cell*, 1984, vol. 37, 1053 [0106]
- **KAUFMAN.** *Proc. Natl. Acad. Sci. USA*, 1985, vol. 82, 689 [0106]
- **MILSTEIN ; CUELLO.** *Nature*, 1983, vol. 305, 537-539 [0109]
- **SURESH et al.** *Methods in Enzymology*, 1986, vol. 121, 210 [0109]
- **BRENNAN et al.** *Science*, 1985, vol. 229, 81 [0109]
- **SHALABY et al.** *J. Exp. Med.*, 1992, vol. 175, 217-225 [0109]
- **KOSTELNY et al.** *J. Immunol.*, 1992, vol. 148 (5), 1547-1553 [0109] [0110]
- **HOLLINGER et al.** *Proc. Natl. Acad. Sci. USA*, 1993, vol. 90, 6444-6448 [0109] [0110]
- **GRUBER et al.** *J. Immunol.*, 1994, vol. 152, 5368 [0109]
- **TUTT et al.** *J. Immunol.*, 1991, vol. 147, 60 [0109]
- **GRUBER et al.** *J. Immunol.*, 1994, vol. 152, 5368 [0110]
- **ZAPATA et al.** *Protein Eng.*, 1995, vol. 8 (10), 1057-1062 [0110]
- **ROGERS et al.** *J. Nucl. Med.*, 1997, vol. 38, 1221-1229 [0113]
- **WELCH ; REDVANLY.** Handbook of Radiopharmaceuticals: Radiochemistry and Applications. John Wiley and Sons, 2003 [0114]
- **LEE et al.** *Bioconjug. Chem*, 1999, vol. 10 (6), 973-8 [0116]
- **KINSTLER et al.** *Advanced Drug Deliveries Reviews*, 2002, vol. 54, 477-485 [0116]
- **ROBERTS et al.** *Advanced Drug Delivery Reviews*, 2002, vol. 54, 459-476 [0116]
- Basic Cell Culture Protocols. **POLLARD ; WALKER.** Methods in Molecular Biology. Humana Press, 1997, vol. 75 [0119]
- Animal cell culture: a practical approach. **MASTERS.** Practical approach series. Oxford University Press, 2000, vol. 232 [0119]
- Human cell culture protocols. **JONES.** Methods in molecular medicine. Humana Press, 1996, vol. 2 [0119]
- **FRANCHINI.** *Hematology*, 2006, vol. 11 (3), 139-146 [0121]
- **HALL ; ROSSE.** *Blood*, 1996, vol. 87 (12), 5332-5340 [0122]
- **MACEY.** Flow Cytometry: principles and applications. Humana Press, 2007 [0127]
- **SALLAH et al.** *Postgraduate Medicine*, 1998, vol. 103, 209-210 [0134]
- **KOTTKE-MARCHANT.** *Hematol Oncol Clin North Am.*, 1994, vol. 8, 809-853 [0134]
- **REDEI et al.** *J Crit Illn*, 1995, vol. 10, 133-137 [0134]
- **BUTKIEWICZ et al.** *Thrombosis Research*, 2006, vol. 118 (2), 199-204 [0134]
- **TOMITA et al.** *Am J Hematol*, 2000, vol. 63 (3), 131-135 [0134]
- **SCHREZENMEIER et al.** *Br JHaematol*, 1998, vol. 100 (3), 571-576 [0134]
- **KUTER ; BEGLEY.** *Blood*, 2002, vol. 100, 3457-3469 [0135]
- **LI et al.** *Blood*, 2001, vol. 98, 3241-3248 [0135]
- **VADHAN-RAJ et al.** *Ann Intern Med*, 2000, vol. 132, 364-368 [0135]
- **KAPLAN.** *Curr Opin Investig Drugs*, 2002, vol. 3 (7), 1017-23 [0141]
- **HILL.** *Clin Adv Hematol Oncol*, 2005, vol. 3 (11), 849-50 [0141]
- **ROTHER et al.** *Nature Biotechnology*, 2007, vol. 25 (11), 1256-1488 [0141]
- **WHISS.** *Curr Opin Investig Drugs*, 2002, vol. 3 (6), 870-7 [0141]
- **PATEL et al.** *Drugs Today (Barc)*, 2005, vol. 41 (3), 165-70 [0141]
- **THOMAS et al.** *Mol Immunol.*, 1996, vol. 33 (17-18), 1389-401 [0141]

专利名称(译)	用于检测PNH II型白细胞的试剂和方法及其作为血栓性疾病的风险因子的鉴定		
公开(公告)号	EP2499494B1	公开(公告)日	2017-03-08
申请号	EP2010829274	申请日	2010-11-09
申请(专利权)人(译)	ALEXION制药公司.		
当前申请(专利权)人(译)	ALEXION制药公司.		
[标]发明人	MOVALIA MAYUR ILLINGWORTH ANDREA FAAS MCKNIGHT SUSAN ROTHER RUSSELL P		
发明人	MOVALIA, MAYUR ILLINGWORTH, ANDREA FAAS MCKNIGHT, SUSAN ROTHER, RUSSELL, P.		
IPC分类号	G01N33/577 G01N33/53 G01N33/50 G01N33/68		
CPC分类号	G01N33/5094 A61K31/352 A61K31/56 A61K31/727 A61K35/19 A61K38/196 A61K38/4886 C07K16/40 G01N33/56972 G01N33/6893 G01N2800/226		
代理机构(译)	øYOUNG & CO LLP		
优先权	61/280897 2009-11-09 US		
其他公开文献	EP2499494A1 EP2499494A4		
外部链接	Espacenet		

摘要(译)

本公开涉及用于检测生物样品中的PNH II型细胞群的方法，以及基于患者血液中PNH II型细胞的百分比确定患者是否具有增加的血小板减少症或血栓形成风险的方法。本公开内容还描述了用于该方法的试剂和缀合物。




(11) EP 2 499 494 B 1

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention of the grant of the patent: 08.03.2017 Bulletin 2017/110

(51) Int. Cl.: G01N 33/577 (2006.01) G01N 33/53 (2006.01) G01N 33/56972 (2013.01) G01N 33/6893 (2013.01)

(54) REAGENTS AND METHODS FOR DETECTING PNH TYPE II WHITE BLOOD CELLS AND THEIR IDENTIFICATION AS RISK FACTORS FOR THROMBOTIC DISORDERS

(58) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IL IT LI LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA ME

(72) Inventor: MOVALIA, Mayur; ILLINGWORTH, Andrea; FAAS MCKNIGHT, Susan; ROTHER, Russell P.; RUSSELL, P. (US)

(74) Representative: ø Young & Co LLP, 125 Holborn, London EC1A 1DU (GB)

(56) References cited: US-A1-2007-118710; US-B1-8-893-898

Note: Upon receipt of the publication of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

(Cont. next page)

EP 2 499 494 B1